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1. INTRODUCTION 
 The predominant aim and object of siddha science is to assure the full span of 
long healthy life to enable man acquired knowledge, Cultivate good character and 
conduct with which they could enjoy their legitimate worldly pleasures and ultimately 
attain salvation.  
Siddha system is a psychosomatic system of medicine that deals with the 
relationship between the mind and body and aims at maintaining the physical, mental and 
moral health of individual. 
As per the Siddha system, man is regarded as the microcosm and universe the 
macrocosm. The forces in the microcosm or man are identical with forces of the 
macrocosm. The living man is a conglomeration of three thodams (Three humors namely 
vadham, pitham and Kabham), Udalthathukkal (Saram, Senneer, Oon, Kozhuppu, Enbu, 
Moolai andSukkilam) and panchabhutham (Five basic elements – Prithivi (Mann), Theyu 
(Thee), Appu (Neer), Kaatru (Vaayu) and Veli (Aagasam). A Suitable proportion of these 
five elements, in combination with one another are responsible for the different structure 
and function of the body matrix.  
Health is considered as the maintenance of equilibrium between the three humors 
and disease is the imbalance among them. The intrinsic and extrinsic factors can cause 
disturbance in this natural equilibrium giving rise to disease. As per ancient siddha text, 
Theraiyar karisal, any disease is caused due to Karma, Irregular dietary habits and 
lifestyle. Saint Thiruvalluvar has indicated the same view in the ancient Tamil literature, 
Thirukural as follows:       
“Miginum kuraiyinum noi seyum noolor 
      Vali mudhala enniya moondru”.  
The siddha system strongly advocates proper food habits and hygiene. It has 
talked of micro-organism that is capable of producing disease. This system not only aims 
at curing a disease but also claims the prevention of the disease, maintenance and 
promotion of health as well said “Prevention is better than cure”. 
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 Siddhars have classified disease into 4448 types and its treatment. One of the 
literatures in siddha is Balavagadam which deals with pediatric disease and its 
management.  
Kanam has been classified into 24 types according to Balavagadam. Vali Kanam 
is one of the subtype of Kanam. The signs and symptoms of Vali Kanam described in 
literature of siddha system correlates with Acute Pharyngitis. Vali Kanam has the 
symptoms of cough, low grade fever, lack of appetite, sore throat, rumbling noise in 
stomach, dysuria and excessive thirst. The etiology of the disease is due to maternal food 
habits during the antenatal and postnatal period.   
Acute Pharyngitis is defined as an inflammation of pharynx. It is most often 
referred to simply as sore throat. It is usually associated with viruses or streptococcus 
pyogenes.Approximately 40-60% of cases of sore throat are caused by a virus such as 
adenovirus, rhinovirus, epstein-barr virus, influenza virus and about 15% are associated 
with streptococcal infection. It is most common for school going age group of children 
during the winter season. Transmission of this disease occurs mostly by hand contact 
with nasal discharge rather than by the oral contact.  
Most of the medicine in Siddha system is mainly made with herbs and herbo-
mineral drugs for pediatric population in order to eliminate this major issue. 
In Balavagadam, a Siddha formulatory text, there is a preparation named Vilva 
Ennai which is indicated for Vali Kanam. This isa poly herbal formulation which mainly 
contains Aegle marmelos and Allium cepa as the main ingredients. Both of these drugs 
are having anti pyretic and anti-inflammatory activity. This drug is commonly used in 
clinical practice. But its efficacy is not evaluated scientifically till now. So the author has 
selected Vilva Ennaifor this dissertation work. 
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2. AIM AND OBJECTIVES 
AIM   
 To evaluate the efficacy of VILVA ENNAI in the treatment of VALI KANAM 
(Acute Pharyngitis). 
PRIMARY OBJECTIVE 
 To determine the therapeutic potential and effectiveness off the drug Vilva Ennai 
in treating Valikanam. 
SECONDARY OBJECTIVES 
 To collect and review the ideas mentioned in the ancient Siddha literature about 
the disease VALI KANAM.  
 To explore Definition, Etiology, Clinical features, Diagnosis, Investigations and 
treatment of VALI KANAM as laid down from various siddha literature. 
 To make the correlative study of the siddha and modern aspect of this diseases. 
 To study the disease VALI KANAM on the basis of three thodam, 
envagaithervugal, neerkuri, neikuri, udalthadhukkal, paruvakaalangal, age, sex 
and economic status. 
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3. REVIEW OF LITERATURE 
    3.1 SIDDHA ASPECT 
3.1.1 ,ay;:(Definition)         
fzk; vd;gJ fh;gr;R+L vdf; $Wth;. ,J Fotpf;F khe;j Neha; Vw;gl;L  
KOtJk; Fzkhfhky; clypy; ,Ue;Nj Kw;wptUk; NehahFk.;   
khjh gpjhf;fspd; ehj tpe;Jf;fslq;fpa thjhjp Njh\q;fspdpd;W 
cw;gj;jpahfpf; fUg;ghraj;J rpRitg; gw;wp mr;rpRthdJ VOtif jhJf;fSk; 
td;ikailAq;fhyj;J mij Nehahy; tUe;j nra;Ak; Neha;. 
  A congenital disease of the child arising from the maturity of bad humours 
inherited from the parents. It is an atrophy resulting from the enlargement of the bowels. 
This disease progresses in several forms as the child advanges in age. (T.V.Sambasivam 
Pillai part II) 
 Foe;ijfSf;F fzr;#l;bdhYk; ghypd; Fw;wj;jpdhYk; tapW 
Nfhshwile;J clk;gpy; fdg;Gz;lhfpr; Ruk;> tpau;it> euk;G typ Kjypad 
Vw;gl;L vYk;G FWfp clk;G ,isj;J tUk; Neha;. 
 A constitutional disease in children arising from congenital heat or bad nutrition 
resulting in diarrhoea of the stomach and glowing head in the body. It is marked by fever 
sweating of the head, nervous affection of the bones, general emaciation. 
(T.V.Sambasivam Pillai).  
rpj;j kUj;Jt E}yhd ghythflk; (Foe;ij kUj;Jtk;);> fzj;jpid %d;W 
tifapy; tiuKiwg;gLj;Jfpd;wJ. mit tUk; topapidg; nghWj;J ,U 
gphpTfSk;> Njhd;Wk; tajpidg; nghWj;J xU gphpTk; MFk.;  
3.1.2 fzk; Njhd;Wk; taJ 
                    “vz;zNt fz%d;W tUle; njhl;Nl 
          Vohz;L kl;Lf;F kpUf;Fq; fhyk;” - ghythflk;. 
taijg; nghWj;J %d;W fUj;Jfs;: 
 3-7 tajpy; cz;lhjy; 
 ghYk; NrhWk; cz;Zk; gUtj;jpy; cz;lhjy; 
 3-12 tajpy; cz;lhjy; 
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3.1.3 Neha; tUk; top (Etiology) 
        “G+q;Foy; khNj Nfsha; 
        Gjy;tUf;F Mz;L nrd;why; 
        ePq;fUk; fizapd; Njh\k; 
         epiwe;jNjhu; euk;ngy;yhk; 
        jhq;fpNa epd;W jhDk; 
        rhUNk Cidg; gw;wp 
        ahq;Fs nuj;j nky;yhk; 
        mKjd; cz;Z nkd;Nw…” 
ghyUf;F Mz;L nrd;why; fizapd; Njhrk; vOfpwJ. ,j;Njhrk; 
euk;ngy;yhk; jq;fp epd;W Cid gw;Wk;. ,jdhy; uj;jk; tw;Wk;. 
             “epiwe;j njhU Mz;bd; Nkyha; 
               gz;LNru; ghyu; nka;apy; 
     gd;dpnuz;lhz;L epw;Fk; 
               Fd;wpdpy; cikahs;f; fPrd; 
   Fwpj;jpij ciuj;jhnud;nw…” 
,g;gb te;j fizNjhrk;> vOe;J nghq;fp ghyfdpd; clk;gpy; 12 Mz;L 
epw;Fk;. Fd;wpd; kPJ tpahgpj;Js;s rptg;gpuhd; cikahSf;F ,ij 
ciuj;Js;shu;. 
       - Foe;ij fiz Neha; kUj;Jtk; 
       “nrhy;ypa nrd;d $w;why; Jlu; gotpidahy; te;J 
            ey;ytdUWg;gpd; rhu;e;J kUtpa Njh\j;jhNy 
        my;yfrpurpy; ePuhy; md;idapd; ghypdhYk; 
            fy;yf euk;gpy; jhtp fgkJ te;JrhUk;” 
fUktpidahYk; cWg;ig rhu;e;j Njhrj;jhYk; jiy ePuhYk;;> md;idapd; 
ghypd; Nfl;lhYk; Foe;ijapd; clypd; euk;gpy; Njhrk; jhtp fgk; Vw;gLfpwJ. 
       “njhifahd fzq;fs; vy;yhk; fh;g;gr;R+L” 
- mNahj;jpjhrh; ghythflk; -193 
 “R+L” vd;gij “clypd; ntg;gepiy” vd;W nfhs;Nthkhdhy; fUTw;w 
fhyj;jpy; jha;khh;fSf;F fpUkp njhw;wpdhy; Ruk; Vw;gl;L> mJ gpwf;Fk; 
Foe;ijiaAk; ghjpg;gjhf nfhs;syhk;. 
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 khwhf „R+L” vd;gij gpj;jk; (m) moy; vd caph;j;jhJthf nfhz;lhy;> 
fUtpd; moy;jhJ khWghL fPo;f;fz;l tifapy; cz;lhfyhk;. 
 fytpapy; Vw;gLk; tpfw;gk;. 
 Rf;fpy> RNuhzpjq;fspd; tpfw;gk;. 
 fUTw;w jha;khh;fspd; czTKiw> nray;ghLfs; ,tw;wpd; 
tpfw;gq;fs;. 
fytpapy; Vw;gLk; tpfw;gk; 
vz;nza; Nja;j;J %o;fpagpd;> clNd czT mUe;jp> cwf;fk; 
nfhs;tjhy; clypd; gpj;jNjhlk; mjpfhpf;Fk;. mNj Neuj;jpy;; cwT 
nfhs;Sk;NghJ cz;lhFk; fUTf;F fzk; cz;lhfyhk; vd;W fUjg;gLfpwJ. 
Rf;fpy> RNuhzpjq;fspd; tpfw;gk; 
 fzkhdJ> khjhgpjhf;fsp;d; ehjtpe;Jf;fSs; mlq;fpa thjhjp 
Njhlq;fspypUe;J cw;gj;jpahfp> fUg;igapd; rpRitg;gw;wp> mr;rpRtpdJ 
rg;jjhJf;fSk; td;ikia milAk; fhyj;jpy; ghjpf;fpd;wJ. (Njhlq;fs; tpUj;jp 
milfpd;wd).             - IPtul;rhkph;jk;  
           “Rf;fpyj;jpy; RNuhzpjq; fyf;Fkd;W 
      GFe;jpLk; tpahjp %d;Wk;”                     
- jd;te;jphp ehb E}y;. 
fUTf;F moy;jhJtpid Nrh;g;gJ Rf;fpykhFk; mjid gpd;tUk; E}y;fs; 
njspthf $Wfpd;wd. 
         ”ghd;ik vd;w tpe;jq;Nf A+Wk;NghJ 
           ghAklh td;dpNahL thAjhNd”;    
 - mfj;jpah; ty;yhjp ehb E}y;. 
           ”cd;dpa fh;g;gf; Fopahk; ntspapNy 
      gd;dpa ehjk; gfh;e;j gpUjptp 
     td;dpAk; thAT khapUQ; Rf;fpyk; 
          kd;dpa rkdha; tsh;f;F KjfNk”  - jpUke;jpuk;. 
fUtpw;F> tpe;JtpypUe;J - thjk;> gpj;jk; vd ,uz;L jhJf;fSk; cjfePh;> 
ehjk; ,tw;wpypUe;J fgKk; fpilf;fpwJ vd fUjg;gLfpwJ 
mNj ghlypy;> 
      “cjfKjpu KWq;fdy; thAthy; 
       rpj FW kq;fq;fs; nra;J Kbj;jpLk;”  
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     cjfkhfpa ePh;> jP kw;Wk; thAtpd; jd;ikahy; nre;ePuhf khwp kw;w 
cly;jhJf;fshd Cz;> nfhOg;G> vd;G> %is> Rf;fpyk; ,tw;iw cz;lhf;Fk; 
vd fUjg;gLfpwJ. 
 vdNt Rf;fpy> RNuhzpjq;fspd; FiwghL> cjfePhpd; FiwghL 
Nghd;wtw;why; fUtpd; caph;j;jhJfspy; xd;whd moy; ghjpg;giltjhy; fzk; 
Vw;gLfpwJ. „fh;g;gr;R+L‟ vd miof;fg;gLtjw;Fk; mJNt fhuzk; vd fUjyhk;.  
fUTw;w jha;khh;fspd; nray;ghLfs; 
      “igau ty;F yhSk; grpAldpUe;j jhYk; 
       Ja;aNjhh; Fotpfl;F fzq;fSe; Njhd;Wkd;Nw” - ghythflk;.                                            
fUTw;w jha;khh;fspd; czT gof;ftof;fq;fs;> nray;ghLfs; 
Nghd;wtw;why; jhapd; clypy; moy;jhJ ghjpg;gile;J mJ fh;ghraj;ijAk; 
jhf;Fk; vd [Ptul;rhkph;jk; vd;w E}ypy; $wg;gl;Ls;sJ. vdNt fUtpd; 
moy;jhJtpy; FiwghL Njhd;Wtjhy; mjd; cly; jhJf;fs; ghjpf;fg;gLfpd;wd. 
,JNt „fh;g;gr;#L‟ vd miof;f fhuzkhfTk; mike;jpUf;Fk;.  
khe;j Nehapd; njhlh;r;rpahf fzk; Njhd;Wk; tpjk; 
khe;jk;: jha; kw;Wk; Foe;ijfspd; czthjp (m) Fzthjp gof;f 
tof;fj;jpy; Fw;wk; NehpLk;NghJ Foe;ijfSf;F Njhd;Wk; nrhpkhdf; NfhshWfs;> 
mjidj; njhlh;e;j czTg;ghij njhlh;ghd cghijfSk; khe;j Neha; vd;W 
miof;fg;gLfpd;wJ. 
czTg;gof;fj;jhy; khe;jk; Njhd;Wjy; 
 cz;Zk; cztpd; nrhpkhdj;jpw;F> 
  rkhdd; - thjk; 
  mdw;gpj;jk; - gpj;jk> 
  fpNyjfk; - fgk;> Mfpa %d;wpd; ,ay;ghd msT 
Kf;fpakhdjhFk;. 
mdw;gpj;jk;  -  czTg;nghUs;fspd; nrhpkhdj;jpy; Kjd;ik gq;F    
tfpf;fpwJ.  
fpNyjfk;   -    cz;Zk; cztpid nkj;njd nra;Ak;.  
rkhdd;   -  Nkw;fz;l ,uz;ilAk; rkepiygLj;jp>rhpahd 
nrhpkhdj;jpw;F cjTfpwJ. ,J nrayw;why; 
nrhpkhdNk elf;fhJ.   
  
8 
 
ke;jhf;fpdp 
Nkw;fz;l %d;wpy; mdw;gpj;jj;jpd; td;ik Fiwe;jhNyh> 
fpNyjfj;jpd; td;ik mjpfhpj;jhNyh> rkhdthA jd; ,aw;if 
epiyapypUe;J jtwpdhNyh ke;jhf;fpdp cz;lhFk;. ,jdhy; czTg; 
nghUl;fs; clNd nrhpg;gpf;fhky;> thAthy; taw;wpiur;ry;> Flypiur;ry;> 
tapw;Wg;gprk; vd;Dk; ,tw;iw cz;lhf;fp neLNeuk; fopj;J nrhpg;gpf;;Fk;. 
vdNt cztpd; rhuk; clYf;F fpilf;fhky; Nghfpd;wJ. 
               “IaJ $bw; nwd;why;  
                mhpitah; Jaue;jd;dhy; 
       nra;a gw; GdyUe;jpr;  
               nrwpry Njhle;jd;dhy; 
        igau ty;FyhSk;  
                grpAldp Ue;jjhYk; 
        Ja;aNjhh; Fotp fl;Ff;  
                    fzq;fSe; Njhd;W kd;Nw”                – (ghythflk;) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
khe;jk; njhlh;e;J epiyg;gjhy; 
fzj;jpd; FwpFzq;fs; Njhd;Wjy; 
cztpd; rhuk; clw;fl;LfSf;F Nrh;tjpy; njha;T 
Vw;gLfpwJ. (tpahddpd; njhopy; ghjpj;jy;) 
rhuk; nre;ePuhf khWk;; Ntiy ghjpj;jy; 
 
kw;w clw;fl;Lfis Nghlzpg;gjpy; rpukk; cz;lhjy; 
clw;fl;Lfspd; td;ik Fiwjy; 
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IaJ $bw;nwd;why;: (Iak; - caph; jhJ) 
Iaj;jpd; ,aw;if epiyfs;> mjd; kpFFzk; Nghd;wtw;iw xg;G Nehf;Fk; 
nghUl;L fPo;fz;lthW njhFf;fg;gLfpd;wJ.  
jd;ik:   
 jd;ik>nea;g;G,nkd;ik>jpz;ik 
 ke;jk;> tOtOg;G  
thOkplk;: 
 rkhdthA> ROKid 
 Mf;fpid> tpe;J 
 ehf;F> cz;zhf;F 
 nfhOg;G> kr;ir 
 FUjp> khh;G 
 euk;G> vYk;G 
,aw;ifg; gz;G: 
 epiyj;jy; 
 nea;g;G 
 fPy;fspd; mikg;gpd; fl;Lfs; 
 nghiwAilik (grp> ePh;Ntl;if;> fyf;fk;> ntg;gk; 
Nghd;wtw;iw nghWj;Jf; nfhs;Sjy;) 
Ia kpFFzk; 
 mf;fpdp ke;jg;gly; 
 cg;gprk; 
 kpFJ}f;fk; cz;lhjy; 
 tha;ePH Cwy; 
 ,iug;G 
 ,Uky;; 
 Cf;fk; Fiwjy; 
 cly; fdkhf Njhd;WtJld; ntz;zpwj;ijAk;> 
Fsph;r;rpiaAk; miljy;. 
 cly; Kw;Wk; cs;s fl;Lfs; jsuy; 
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mhpitah; Jaue; jd;dhy; 
mhpit - ngz;fspd; gUtq;fspy; xd;W. 
20-25 tajhdJ kfsph; kfg;NgW milAk; nghJthd fhyk; vd;gjhy;> ghlypy; 
mhpit vd;w thh;j;ijia Nkw;nfhz;bUg;gij czuyhk;. mg;gUtj;jpy; kfsphpd; 
Jd;gq;fshd cly;eyf;FiwT> nghUshjhuf;FiwT Nghd;wit Foe;ijfSf;F 
gy ,lh;ghl;bidAk;> Fwpg;ghf fzj;jpidAk; cz;lhf;Fk;;. 
nra;a gw;GdyUe;jp nrhpry Njhle;jd;dhy; 
gy;NtWtifg;gl;l ePhpid mUe;Jtjhy; ryNjhlq;fs; cz;lhfp epiyj;J 
fzNeha; Njhd;Wk; vd;gJ nghUshFk;. mj;jifa ePhpd; jd;ik> Fbj;jYf;F 
Mfhj ePH vd rpj;jkUj;Jtj;jpy; $wg;gl;Ls;s fUj;Jfis fhz;Nghk;. 
ePhpd; jd;ik: (rpj;jkUj;Jthq;f RUf;fk;) 
ePuhdJ kdJf;F fspg;igAk;> epiwitAk; cz;lhf;FtJ kl;Lkd;wp 
cl;nfhs;Sk; cztpid ed;wha; clypw; gutr; nra;J clw;F td;ikiaj; 
jUk;. NkYk; cz;l fbd czTg;nghUl;fis nrhpg;gpf;Fk;.  
ePUf;F jdpFzk; ,y;iy. mJ jq;Fk; ,lj;jpd; NtWghLfshNyNa 
ntt;NtW Fzq;fis milfpd;wJ. ,jid>  
              “jz;zPh; Fznky;yhe; jhd; Nfs; klkapNy 
    kz;zpd; Fzky;yhy; kw;Wz;Nlh?” 
                        - Njud; nghUl;gz;G 
 
Fspay;> Fbj;jYf;F Mfhj ePh; 
         “re;jpuh jpj;jh; tsp rhuhj ePh; GOJh;f;  
          fe;jkjp NrW fdg;gpiyA - jphpe;j ePh; 
          jq;FRit apy;yh ePh; rhw;Wkpit ];ehdgh 
          dq;fSf;fh fhTwpNeh ahk;.             
                                                                           - gjhh;j;j Fz rpe;jhkzp 
jpq;fs;> QhapW ,tw;wpd; fjpnuhsp;;; fhw;W ,itfs; mZfhjJk;; fpUkp> 
Jh;ehw;wk;> NrW jbj;jy;> rUF cjpuy;> Ritapd;ik vd;Dk; ,itfs; 
nghUe;jpaJk; Mfpa ePh;> Fspay;> Fbj;jy; ,itfl;F MfhJ. ,ij cz;zpd; 
Nehia cz;lhf;Fk;. 
NkYk;> 
“Jiyahf; fpzNw fae;jpul;Lk; ”  
      - ,iwg;gpy;yh fpzw;W ePh; fgg;gpzp cz;lhf;Fk;. 
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           “tsh;f;FQ; Ruj;ij rU$wy;”     
    - rUF Cwpa ePh; Ruk; tsh;f;Fk;. 
           “khwhf; FsNk tpahjpAz;L”    
   - gad;gLj;jhj Fsj;JePh; tpahjp cz;lhf;Fk;.  
   mt;thW gy;NtWgl;l ePhpid mUe;Jtjpdhy; ryNjhlk; Vw;gl;L  fzNeha; 
Njhd;Wk; vd;W $wg;gLfpd;wJ. 
igau ty;FyhSk; grpAldpUe;jjhYk; 
(igau - #y;nfhz;l: ty;Fyhs; - #Yw;w ngz;fs;).  
#Yw;w ngz;fs rhptpfpj cztpid cz;zhjjhy; mth;fspd; cly;eyd; 
Fd;wp mJ Foe;ijfspd; tsh;r;rpiaAk; fzNeha; Njhd;Wtpf;Fk.; 
gpw E}y;fs; fUj;J  
 jpUts;Stehadhh; ,aw;wpa etuj;jpdrpe;jhkzp 800 y; $wpathW 
je;ijapd; Ntl;ifahy; gpz;lk; fdypy; mbgl;L fzk; tUtjhf 
$wg;gl;Ls;sJ. 
 “ghuhd nfw;gntl;il kPUk; gf;Ftj;jpy; 
  Ntuhd tphpe;J ntspg; gl;L Nahdp tpOe;j njd;whw; 
  fhuhd gpz;lq; fdypyb gl;Lf; fhe;jpdpdhw; 
  $uha; fzRu nka;J nkd;Nwahd; $wpNdNk” 
 jd;te;jphp itj;jpak; vDk; E}y; fzkhdJ G+h;tn[d;kq;fspy; nra;j 
jPtpidfis je;ijahfTk;> ,g;gpwg;gpy; nra;Ak; jPtpidfis jhahfTk; 
mile;J “raf; Fkhud;” gpwf;fpwhd; vd;W $WfpwJ. 
           “rPhpa njhd;ik nra;j jPtpid je;ijahfg; 
  ghhpypg; gpwg;gpw; nra;j ghtNk jhajhfg; 
  Nghpar; raf; Fkhud; tpwe;jpyh fpw kj;jg;Ng 
  fhhpa nrtpypj; jhaha; „fzk;‟ ngw tsUk; ehspy;”;….. 
3.1.4 fzj;jpd; tiffs; (Types) 
 gy;NtW E}y;fs; ntt;NtW vz;zpf;iffspy; fzj;jpid njhFf;fpd;wd. 
gps;isg;gpzp kUj;Jtj;jpy; $wg;gl;Ls;s fzq;fs;-64 tiffs; 
1. tspfzk;    33. mow;fzk; 
2. Ia fzk;   34. khe;j fzk; 
3. ePh;f;fzk;    35. gpuspf;fzk; 
4. #ypfzk;    36. Ropfzk; 
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5. kfhfzk;    37. CJfzk; 
6. tus;fzk;    38. nfhjpg;G fzk; 
7. tPf;f fzk;   39. gpwf; fzk; 
8. mf;fu fzk;   40. ke;jhu fzk; 
9. vhp fzk;    41. ePuhk fzk; 
10. ,uj;j fzk   42. Kf;F fzk; 
11. %y fzk;   43. Nguhk fzk; 
12. cyup fzk;   44. rpq;fp khe;j fzk; 
13. Mk fzk;   45. Rj;jp fzk; 
14. czf;F fzk;   46. ru;g;g fzk; 
15. cd;Nuhffzk;   47. rpj;ufzk; 
16. CJkhe;j fzk;   48. Rufzk; 
17. fug;ghd; fzk;   49. jdpRufzk; 
18. fsp;fzk;    50. mjpRu fzk; 
19. Fly;Nrhif fzk;  51. J}q;F fzk; 
20. FlNyw;w fzk;   52. njw;fj;jp fzk; 
21. vhp fzk;    53. njw;fj;J khe;j fzk; 
22. ,uj;j fzk;   54. ePuhk;g fzk; 
23. %y fzk;   55. gl;rp fzk; 
24. kNfe;jpu fzk;   56. ghy fzk; 
25. ke;jhu fzk;   57. %yhjhu fzk; 
26. Nkf fzk;   58. thA fzk; 
27. thNte;jpu fzk;   59. thyre;jpu fzk; 
     28. tp\ fzk;   60. tp\ePu; fzk; 
     29. tp\ghf fzk;   61. tp\ khe;j fzk; 
     30. tpujp fzk;   62. tPq;F fzk; 
     31. ntg;G fzk;   63. Fd;wp mf;fu fzk; 
     32. nghUK fzk;             64. KbNyhf fzk; 
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Mj;kul;rhkph;jk; vd;Dk; itj;jpa rhuq;f rq;fpufk;    
  - fe;jrhkp Kjypahh;; 
1. thj fzk;   13. gpj;j fzk; 
2. rpNyj;Jk fzk;   14. khe;j fzk; 
3. ePh;f; fzk;   15. gpusp fzk; 
4. #iyf; fzk;   16. Rop fzk; 
5. kfh fzk;   17. CJ fzk; 
6. twl;rp fzk;   18. nfhjpg;G fzk; 
7. tPf;f fzk;   19. gpwf; fzk; 
8. Mkf; fzk;   20. twl;rp fzk; 
9. Kf;F fzk;   21. Nghh;f; fzk; 
10. ,uj;j fzk;   22. er;R khe;j fzk; 
11. CJ khe;j fzk;   23. vhp fzk; 
12. ke;jhu fzk; 
mNahj;jpjhrh; ghythflk; 24 tiffs; - gf;fk; - 180; gjpg;G 1992 
1. tspfzk;    13. tPf;f fzk;     
2. mow;fzk;   14. gpwf; fzk; 
3. Ia fzk;   15. me;jf fzk; 
4. khe;j fzk;   16. ke;jhu fzk 
5. ePh;f;fzk;    17. vhp fzk 
6. gpuspf;fzk;   18. ePuhk fzk; 
7. #ypfzk;    19. Mk fzk; 
8. Ropfzk;    20. Kf;F fzk; 
9. kfhfzk;    21. %y fzk; 
10. CJfzk;    22. Nguhk fzk; 
11. tus;fzk;    23. uj;j fzk;     
12. nfhjpg;G fzk;   24. rpq;fp khe;j fzk 
guuhr Nrfuk; ghyNuhf epjhdk; - 18 tiffs; 
1. thj fiz       10. gpj;j fiz 
2. Ruf; fiz       11. mj;jpRu fiz 
3. twl;fiz       12. thyre;jpufiz 
4. kNfe;jpu fiz   13. J}f;F fiz 
5. mdw; fiz   14. tPq;F fiz 
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6. ntSg;Gfiz   15. rj;jp fiz 
7. ,uj;j fiz   16. %yf;fiz 
8. fUq;fiz   17. kQ;rl; fiz 
9. epyf; fiz   18. ntg;G fiz 
gps;isg;gpzp thflk; - 8 tiffs; 
1. ePh; fzk;    5. tus; fzk; 
2. %yfzk;    6. rPjfzk; 
3. ,ja fzk;   7. kfhfzk; 
4. kyf;fzk;   8. Fz;lypa fzk; 
[Ptul;rhkph;jk; 8 tiffs; 
1. #ypfzk;    5. Kf;F fzk; 
2. Mkfzk;    6. Njiufzk; 
3. kfhfzk;    7. Ropfzk; 
4. fopfzk;    8. tws;fzk; 
3.1.5 fzj;jpd; nghJ Fzq;fs; 
ghythflk; $Wk; Nehapd; Fzq;fs; 
 Foe;ijfSf;F khe;j Neha; gyKiw te;J Kw;wpYk; Fzkilahky; 
,Ug;gjhy; ,e;Neha; cz;lhFk;. 
 gpj;jkhdJ mjpfkhfp thAf;fs; jd; Ntiyia nra;a Kbahky; 
jLj;JtpLk;. mjdhy; Foe;ijfspd; clypy; Vw;gl;l #L ve;NeuKk; 
tplhJ fhZk;. 
 Ruk; fha;jy; 
 ,Uky; 
 %r;R thq;Fjy; 
 cly; Nrhh;tiljy; 
 tapW Nehjy; 
 tapW fopjy;  
- kyk; vz;nza; frpthdjhf ,Uf;Fk; 
- rPjkhf> ,uj;jkhf (m) ,uj;jKk;> rPjKk; fye;J  
Ngjpahjy; 
- ghy; Nghy ntz;zpwkhf fopjy; 
- Cz; fOtpa jz;zPh; Nghy; Ngjpahjy; 
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- kytha; vhpr;ry; 
- kyk; ntl;ilahjy; (kyr;rpf;fy;)  
 cr;rpapy; Fop tpOjy; 
 Kfk; Nrhh;tile;J fhZjy; 
 Fuy; fk;kyhf NgRjy; 
 if> fhy;> Kfk; twz;L fhZk; 
 mdy; tPRtJ Nghd;W cl;Ruk; fhzy; 
 tha;ehw;wk; 
 khh;G $k;G Nghy; vOk;gp fhzy; 
 ePh; RUq;fy; 
fzj;jpy; xd;Wld; xd;W njhlh;Gfsw;w gy FwpFzq;fs; njhFg;ghff; 
fhzg;gLfpd;wd. mjdhy; fzj;jpy; gy Neha; epiyfs; ,Ug;gjid mwpayhk.; 
NkYk; nghJf;FwpFzq;fis gpujhdkhff; nfhz;L> fzj;jpd; rpwg;G 
Fzq;fSld; nghUj;jp (fzj;jpd; tiffs;) Nehapid fzpj;jy; rpwg;ghdjhFk;.  
gpw E}y;fspy; fhZk; fzj;jpd; nghJFzq;fis mwpe;J nfhs;Sk;NghJ> 
Nehapid Fwpj;j njspthd xg;GNehf;F nra;a KbAk; vd;gjhy; mjidAk; 
fhz;Nghk;;. 
mgpjhd rpe;jhkzp $Wk; Nehapd; Fzq;fs; 
 khh;gpy; tPf;fk; 
 cl;Ruk; Ruk; 
 twz;l kyk; 
[Ptul;rhkph;jk; $Wk; Nehapd; Fzq;fs;: 
 tha;ehw;wk; 
 jiyRw;wy; 
 cs;Ruk; (my;yJ) 
 xU Ntis ntspRuk; (my;yJ) 
 tapw;wpd; Nky; RLjy; 
 kaf;fk; 
 twz;l kyk; 
,f;Fzq;fs; rfy fzj;jpw;Fk; nghJthf tUk; vd mwpf. 
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cs;Ruk; Fwpj;j tpsf;fk;: 
mf];jpah; RuE}y; 300 - „rpj;jkUj;Jtk; - nghJ‟ gf;fk; 57 - 6k; gjpg;G 
vd;w E}ypy; „RukNj fizajhFk;” vd $wg;gl;Ls;sJ. 
mjd; tpsf;fj;jpy; Foe;ijfSf;F Njhd;Wfpd;w vd;GRuk;> moy; Ruk;> 
khe;jRuk; Nghd;witfs; Foe;ijfis tUj;jkilar; nra;J> gpd;dh; fiz 
Nehapid gpwg;gpf;Fk;. 
fzk; - Ruk; njhlh;G : 
  „fiz Nehapy; cl;Rukhf fhAk;” 
         rpj;jkUj;Jtk; - nghJ 
  „fizapy; fhe;js; kyh; Nghd;w Ruk; fhZk;” 
 Nkw;fz;l Nkw;Nfhs;fs;> fzj;jpy; Ruj;jpw;Fk; gpw Neha; epiyfspy; 
fhZk; Ruj;jpw;Fk; NtWghL cz;L vd;gij njspthf $Wfpd;wd. 
(fhe;js; kyh; vd;gJ jP G+jj;Jld; njhlh;G nfhz;lJ. me;j kyhpd; my;yp 
,jo;fs; RUf;fkhdjhf fhZk.; fiz NehapYk;> njhlh;e;J cl;Ruk; cs;s 
Foe;ijfs; cly; Nrhh;tile;J fhZtjhf nghJ FwpFzj;jpy; Fwpg;gplg;gLtJ 
rpwg;ghFk;). 
„cl;Ruk;” vd;gJ gpw Ruq;fspypUe;J NtWgl;lJ. ,r;Ruk;> cly; td;ik 
Fiwe;j Ngh;f;F ntspf;F njhpahky; clypd; cs;Ns jfpj;J> Ruk; ,Ug;gJ 
Nghd;W fhzg;gl;L> Nrhfk;> kdj;jsh;r;rp> iffhy; Xa;r;ry;> cztpy; 
tpUg;gkp;d;ik> tha;f;Fkl;ly;> vg;NghJk; Ruk; fha;tJ NghypUj;jy;> cly; 
nkype;J nfhz;Nl nry;Yjy; vd;Dk; Fwp Fzq;fis gpwg;gpf;Fk;.   
           - rpj;jkUj;Jtk; - nghJ - gf;fk; - 36. 
ghythflk; E}ypd;gb tsp fzj;jpd; FwpFzq;fs; 
 “thj fzj;jpd; Fzj;jpay;ig 
      tFg;Nghk; clYk; ghukjha; 
       Nghj ,iuf;Fk; ehtuSk; 
            Gife;Nj ,UKw jhfKld; 
       thj fzj;jpd; Fzj;jpay;ig 
        tFg;Nghk; clYk; ghujkha;g; 
       Ngj khf ePu;r;RUf;fhk;”; 
 tapW ,iuAk; 
 eh tuSk; 
 Gifr;ry; 
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 ,Uky; 
 mjpf jhfk; 
 Ruk; 
 grpapd;ik 
 ePu;r;RUf;F 
[Ptul;rhkph;jk; - E}ypd; gb tsp fzj;jpd; FwpFzq;fs; 
 tapW ,iuAk; 
 eh tuSk; 
 ,Uky; 
 mjpf jhfk; 
 Ruk; 
 grpapd;ik 
 ePu;r;RUf;F 
 kyk; ,WFk; 
Mj;kul;rhkph;jk; E}ypd; gb tsp fzj;jpd; FwpFzq;fs;: 
 tapW ,iuAk; 
 eh tuSk; 
 Gifr;ry; 
 ,Uky; 
 mjpf jhfk; 
 Ruk; 
 grpapd;ik 
 ePu;r;RUf;F 
 kyk; ,WFk; 
guuhrNrfuk; - ghyNuhf epjhdk; E}ypd; gb tsp fzj;jpd; FwpFzq;fs; 
    “thj fzj;jpd; Fzj;jpay; tFg;Nghk; clYk; ghukjha; 
     Nghj ,iuf;Fk; ehtuSk; Gife;Nj ,UKw jhfKld; 
     thj fzj;jpd; Fzj;jpay;ig tFg;Nghk; clYk; ghujkha;g; 
     Ngj khf ePu;r;RUf;fhk;”; 
 tapW ,iuAk; 
 eh tuSk; 
 Gifr;ry; 
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 ,Uky; 
 mjpf jhfk; 
 Ruk;  
 ePu;r;RUf;F 
 grpapd;ik 
 kyk; ,WFk; 
3.1.6 Neha; fzpg;G: (Diagnosis) 
Piniyari muraimai is a method of diagnosing a disease. Siddha system has a very 
unique method of diagnosis. 
  “Pini” means    =   Disease 
  “Ari” means  = Identify 
  “Muraimai” means   =   Method. 
This is based upon three main principles and Envagai Thervugal. The three main 
principles are, 
1. Poriyal arithal (Inspection) 
2. Pulanal arithal ( Palpation) 
3. Vinathal ( Interrogation) 
 Physician‟s „Pori‟ and „Pulan‟ are used as tools for examining the „Pori Pulan‟ of 
the patients. The above principles correspond to the methodology of Inspection, Palpation 
and Interrogation in modern medicine, in arriving a clinical diagnosis of the disease. 
Poriyaal arithal: (Inspection) 
Porigal are considered as the five senses of perception namely, 
1. Nose  
2. Tongue   
3. Eye    
4. Skin  
5. Ear 
 Pulanal arithal: (Palpation) 
  Pulangal are functions of five senses. They are, 
1. Smell  
2. Taste   
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3. Vision                                                                                                                                                                                                                                                                                                                               
4. Sensation of Touch  
5. Hearing 
Vinathal: (Interrogation) 
Vinathal is asking the information regarding the history of the disease, its clinical 
feature etc., from the patient or his/her close relatives who are taking care of him/her.     
 rpj;j kUj;Jtj;jpd; Neha;fzpg;gpy; gpd;tUk; fhuzpfs; Kf;fpa gq;F 
tfpf;fpd;wd. 
Nehahspiar; rhh;e;jJ 
1. caph; jhJf;fs; (Kf;Fw;wk;) 
2. cly; jhJf;fs; (VO clw;fl;Lfs;) 
3. vz;tifj; Njh;T  
Nehahspiar; rhuhjJ 
4. nghOJ 
   rpWnghOJ -  itfiw> tpbay;> vw;ghL> ez;gfy;> khiy> ahkk; 
  ngUk;nghOJ-fhh;> $jph;> Kd;gdp> gpd;gdp> ,sNtdpy;> KJNtdpy; 
5. Itif epyq;fs; : FwpQ;rp> Ky;iy> kUjk;> nea;jy;> ghiy. 
Nkw;$wpa fhuzpfspd; khWghLfis xd;Wld; xd;W xg;gpl;L Neha; 
fzpf;fg;gLfpwJ. 
caph; jhJf;fs; (Kf;Fw;wk;) 
tsp fzj;jpy; Kf;Fw;w tpfw;gk; 
thjk;> gpj;jk;> fgk; Mfpa %d;W jhJf;fspy; rkr;rPH epiyapy; cz;lhFk; 
NtWghLfis Nehahf cw;gj;jpahfpwJ. 
(m)  „eLq;fpaNjhh; gpj;jkJ Nfhgq; nfhz;L 
     ey;ythAit gw;wp aOj;jpf; nfhs;Sk; - ghy thflk; 
Kjypy; gpj;jNjhlk; ghjpg;gile;J (jd;dpiy tsh;r;rp mile;J) gpd;G 
tspFw;wj;jpd; njhopiyAk; (Ntw;Wepiy tsh;r;rp mile;J) ghjpg;gjhf 
nfhs;syhk;. ,Nj fUj;ij „ke;jkyhJ thAtuhJ” - Neha;ehly; Kjy; ghfk; 
vd;w Njud; Nrfug;gh ghlyhy; ke;jj;jpdhy; thA cz;lhFk; vd mwpayhk;. 
NkYk; khe;jk; (ke;jk;) vd;gJ gpj;jj;jpd; jd;dpiy tsh;r;rp Fzk; vd 
mwpaNtz;Lk;. 
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(M)  „IaJ $bw; nwd;why;”   -  ghy thflk; 
,jd; nghUs; Iaf;Fw;wk; jd;dpiyapy; tsh;r;rp miljy; vd;gjhFk;  
,Nj fUj;ij “fgj;jpidad;wp fhrRthrk; fhzhNj” - (Neha;ehly; Kjy; 
ghfk;); vd;w Njud;Nrfug;gh ghlyhy; Iaf;Fw;wj;jpd; jd;dpiy tsh;r;rpad;wp 
fzj;jpd; FwpFzkhd fhrk;> Rthrk; tuhJ vd mwpayhk;.  
moy; Fw;wk; jd;dstpy; kpFe;J thAit gw;wp mOj;jpf; nfhs;Sk;. 
mjdhy; clypy; mjpfg;gl;l moy; jzptjw;F topapy;yhky; Foe;ijf;F 
mjpfkhf #L cz;lhfp cly; fdfdg;G Vw;gLfpd;wJ. 
tsp fzj;jpy; cly;jhJf;fspd; epiy 
cz;l cztpd; md;drhukhdJ Flypy; cwpQ;rg;gl;L clw; jhJf;fshd 
rhuk;> nre;ePh;> Cz;> nfhOg;G> vd;G> %is> Rf;fpyk; (m) RNuhzpjk; 
Nghd;wtw;iw Nghlzpf;fpd;wJ vd cly;jj;Jt E}y;fs; $Wfpd;wd. 
 “je;jpL euk;g njy;yhe; jhq;fpNa A+izg; gw;wp 
 ce;jpL kpuj;jnky;yh kKnjd Tz;Z kd;Nw” 
                    -guuhrNrfuk;-ghyNuhf epjhdk; ghly;: 269 
vd;w ghlyhy; fiz Neha; cly; jhJf;fis ghjpf;Fk; vd mwpayhk.; 
fizapy; cly; jhJf;fs; Nghlzpf;fg;gLtjpYk;> cUthf;fj;jpYk; rpukk; 
Vw;gLfpwJ vd;gjhy; Neha; jPtpuj;jpw;F Vw;g midj;J jhJf;fSk; (Rf;fpy> 
RNuhzpjk; cs;gl) thpirahf xd;wd;gpd; xd;whf ghjpg;gilAk; vd 
fUjg;gLfpwJ. Rf;fpyk;> RNuhzpjk; ,tw;iw Neubahf tpe;J> ehjk; vd;W 
nghUs; nfhs;shky;> cly; nry;fs; kw;Wk; cWg;Gfs; jd;idnahj;j cUtg; 
ngUf;fpw;F Kjyha; epw;Fk; cly; jhJ vd nghUs; nfhs;tJ rpwg;ghFk;.  
tsp fzj;jpy; vz;tifj; Njh;Tfs;: 
nghwp> Gyd;fshy; mwpjy;> tpdhjy; Nghd;witfspd; %yk; kUj;Jth; 
mwpe;jtw;iw vz;tifj; Njh;Tfs; %yk; cWjpgLj;j Ntz;Lk;. 
 “ehb ];ghprk; eh epwk; nkhop tpop 
  kyk; %j;jpukpit kUj;JtuhAjk; - Neha;ehly; Kjy; ghfk;        
          ”Njba tpahjpf; nfy;yk; Njfj;jpy; ghpl;irAz;L 
  $bNa epw;Fnkl;L ghpl;irahq; $wf;NfsPh; 
  ehbNa njhl;lhw; Njfk; %j;jpuk; thh;j;ij fz;fs; ehf;F 
  ghbNa kyryq;fs; gy tz;zk; ghh;j;Jf; nfhs;Ns” 
      -  rpj;j kUj;Jtkzpfs; 
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Nkw;$wpa ghlypd; %yk; ehb> ];ghprk;> eh> epwk;> nkhop> tpop> kyk;;> 
%j;jpuk; Mfpad kUj;Jthpd; MAjk; Nghd;wit vd mwpayhk;. 
ehb 
vz;tifj; Njh;Tfspy; gpujhdkhdJ. gpzpapid ehbahywpe;J 
kUe;J}l;LjNy rpwe;jJ vd;W rpj;j kUj;Jtk; $Wfpd;wJ. Mdhy; Foe;ijfspy; 
ehbeil rhpahf Njhd;whJ vd;gij fPo;fz;l ghlyhy; mwpayhk;. 
 “nfhz;blNt faNuhfp fhrNuhfp 
  Fwpg;ghf rpw;wpd;gk; nra;j Ngh;fs; 
  mz;blNt jhpj;jpuh;fs; tpUj;jh; ghyh; 
  nfhz;blNt ,th;fspd; cWg;gpd; jhJ 
  $wNt KbahJ vth;f;Ff; fpl;Lk;.” 
                   -Neha;ehly; Neha; Kjy;ehly; jpul;L 
vdpDk; fzj;jpy; gpj;jFw;wk; Kjd;ikahf ghjpj;J gpd; thj> fg 
Fw;wq;fSk; ghjpg;gjhy;> fPo;fz;l ehbeilahdJ Njh;thsuhy; ghpNrhjpj;J 
vOjg;gl;lJ. 
- gpj;jfgk;> gpj;jthjk; kw;Wk; thjgpj;jk; 
];ghprk; 
Nehahspapid njhl;L ghh;j;jypd; %yk; czug;gLk; FwpFzq;fs; MFk.; 
tsp fzNehapy; fPo;f;fhZk; FwpFzq;fs; mt;thW czug;gl;lJ. 
- tapWtyp; 
- Ruk; 
- cl;Ruk; 
eh 
 Nehahshpd; ehf;fpid ghh;j;J czug;gLk; fzNehapd; FwpFzq;fshtd. 
- nre;ePh;j;jhJ Fiwe;J fhZjiy> eh ntspwpl;L ,Uj;jyhy; 
mwpayhk;. 
epwk; 
 tsp fzNehapy; clw;fl;Lfs; td;ik Fiwe;Js;sij mwpa 
epwg;ghpNrhjid gad;gLk;. 
 Njhypd; epwk;  -  ntspwpf;fhZjy; 
       fWj;Jf;fhZjy; 
 eh> fz;  -  ntspwpf;fhZjy; 
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nkhop 
tsp fzNeha; Foe;ijfspy; fgk; mjpfhpf;Fk; fhuzj;jhy; Fuy;fk;ky; 
Njhd;wp jho;e;J NgRth;. 
tpop 
 tpopr;Nrhjidapy;> fzNehapd; fPo;f;fhZk; FwpFzk; czug;gl;lJ. 
- fPopik ntspwpf;fhZjy; 
kyk; 
 fzNeha; Foe;ijfspy;> tpdhjypd; %yk fPo;fz;l FwpFzq;fs;mwpayhk;. 
- fopr;ry; 
- kyr;rpf;fy; 
%j;jpuk; 
     Foe;ijfspy;> Ngjp ,Ue;jhy; clypd; ePh;j;Jtk; Fiwe;J ePh;;;;;;tuj;J 
Fiwe;J fhZk;. 
ePh;f;Fwp 
  “te;j ePh; fhpnail kzk; Eiu vQ;rnyd; 
   iwe;jpaYsit aiwFJ KiwNa” - Neha; ehly; Kjy; ghfk; 
   ePhpy; epwk;> kzk;> Eiu> vil> vQ;ry;> Mfpatw;iw Nehf;f Ntz;Lk;. 
nea;f;Fwp 
Foe;ijfspd; ehbeil rhpahf fzpg;gjpy; rpukk; cs;sjhy;> nea;f;Fwp 
ghpNrhjid %yk; Nehahsh; vf;Fw;wj;jhy; ghjpf;fg;gl;Ls;shh; vd;gjid 
fzpf;fyhk;. 
 fzNehahspapd; rpWePiu Nrhjid tl;bypy; Cw;wp xsp kpFe;j ,lj;jpy; 
ePhpd; miyapy;yhj NghJ ey;nyz;nzaj;;Jsp tp;l;L ghh;f;fg;gl;lJ. 
rpyhpy; Mop Nghy; (Nkhjpuk;) gutpAk;> rpyhpy; Kj;JNghy; epd;Wk; 
fhzg;gl;lJ. 
 “muntd ePz;bd; m/Nj thjk; 
 MopNghw; gutpd; m/Nj gpj;jk; 
 Kj;njhj;J epw;fpd; nkhoptnjd; fgNk” 
                            - Neha; ehly; Kjy; ghfk; 
3.1.7 kUj;Jtk; 
1. Ntw;Wepiy tsh;r;rpaile;j gpj;jj;jpid jd;dpiyg;gLj;j Ntz;Lk; 
2. jd;dpiy tsh;r;rpaile;j Iaj;jpid rkg;gLj;j Ntz;Lk; 
3. gpj;jFw;wj;jhy; ghjpg;gile;Js;s thjj;jpidAk; rhpg;gLj;j Ntz;Lk;. 
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4. td;ik ,oe;j clw;fl;Lfis td;ik milar;nra;Ak; tifapy; 
kUe;jspf;f Ntz;Lk;. 
Keeping in mind the need for bringing out an effective therapy for Vali Kanam 
from Siddha system of   Medicine, the author has undergone this dissertation work with 
Vilva Ennai. 
The dosage of medicine is 3 ml (od) 
Line of Treatment 
 Siddha treatment is not only for complete healing but also for prevention and 
rejuvenation. Saint Thiruvalluvar says about physician‟s duty as study the disease, study 
the cause, treat subsiding way and do what is proper and effect. 
 “Neha; ehb Neha; Kjy; ehb mJ jzpf;Fk; 
  tha; ehb tha;g;gr; nray;”. 
 “cw;whd sTk; gpzpasTq; fhyKq; 
  fw;whd; fUjpr; nray;”. 
      - jpUf;Fws; 
 So it is essential to know the disease, the etiology, the nature of patients, severity 
of the illness, the seasons and the time of occurrence. 
Line of treatment is as follows. 
1. Kaappu (Prevention) 
2. Neekkam (Treatment) 
3. Niraivu (Restoration) 
Kaappu (Prevention) 
Prevention and cure of the diseases are the basic principle of any medical system, 
but prevention is the main aim of Siddha system. Siddhars have described general 
preventive measures and special measures. (Which are applicable to diseases of certain 
organs) 
            And especially in Balavagadam, the preventive measures are explained in detail. 
Prevention of the disease of the child starts from the conception and goes on as the child 
grows up in intra uterine life and after delivery.  Siddhars have dealt elaborately with the 
diet of pregnant women, her habit, the medicine to be taken in every month, her 
psychological conditions, and surroundings etc. 
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Neekam: (Treatment) 
 The aim of treatment is based on, 
To bring the three thodams into normal equilibrium state, emetics and purgatives 
are given. But considering physical condition of the children administration of purgatives 
and emetics is excluded from line of treatment. 
 Niraivu: (Restoration) 
1. Reassurance of disease recovery was given to all patients. 
2. All the patients are advised to follow the life style that provides a disease free 
life.  
Pathiyam (Diet): 
 During the course of treatment, the drug is administered to the patients according 
to the nature of disease and the patients were advised to follow certain restrictions 
regarding diet and physical activities. 
 This type of medical advice in siddha system of medicine is termed as 
“Pathiyam”. 
Importance of pathiyam is quoted as follows. 
     „gj;jpaj;jpdhNy gyDz;lhFk; kUe;J 
 gj;jpaq;fs; Nghdhy; gyd; NghFk; - gj;jpaj;jpy;  
 gj;jpaNk ntw;wpjUk; gz;bjHf;F Mjypdhy; 
 gj;jpaNk cj;jpnad;W ghH”    
      - NjiuaH ntz;gh 
The patients with Vali Kanam were advised to avoid cool drinks, cold water and 
exposure to chill weather and allergens (dust, pollens, and odours)  
 During the course of treatment, according to the drug administered to the patients 
and nature of the disease, the patients were advised to follow certain precautions 
regarding diet and physical activities. This type of medical advice in Siddha system of 
medicine is termed as Pathiyam.  
Siddhars advice regarding the diet regimen for Kaba patients is explained below:  
 “ fj;jhp Nga;Gly; tiu apUghfy; gUq;fsh fz;lfhhp 
  mj;jpf; fha;fSk; tUf;ifkhgaw;iw fiuahy; gPHf;fUk; - gpQ;RNtH 
  nkha;j;j R+uzq; fjypj; jz;Lfisg; g+Ksq;fp KUf;fUk;Gk; 
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  mj;jpg; g+rzpf; fhaUs;sp ts;spAq; fgj;NjhHf; fhzkhNk” 
“ Ntis kzj;jf;fhsp nkd; rPij rf;utHj;jp 
  gPis triy Rf;F ngz;Rzq;fs; - Ntisapiy 
  nre;jspH fisf; fPiu nra;tH fgNjfH epjk; 
  te;jdpAzj;jhd; kfpo;e;J. ” 
                       -gjhHj;j Fz rpe;jhkzp 
 fj;jhp  
 Nga;Gly; 
 ghfy; 
 fsh 
 mj;jpf;fha; 
 gPHf;;fq;fha; 
 fjypj; jz;L 
 Ks;sq;fp 
 G+rzpf;fha; 
 fUk;G 
 kzj;jf;fhsp 
 triy 
Prevention methods 
 The patients were advised, 
 To find out which agent makes allergy and avoid them. 
 To avoid contaminated food and water and avoid cold weather. 
 To avoid cold food stuffs, beverages etc.  
 To take highly nutritious diet like vegetable soups to get their 
immunity developed 
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3.2 MODERN ASPECT 
3.2.1 RESPIRATORY SYSTEM 
                The cells of the human body require a constant stream of oxygen to stay alive. 
The respiratory system provides oxygen to the body‟s cells while removing carbon 
dioxide, a waste product that can be lethal if allowed to accumulate.  
                The 3 major parts of the respiratory system are the airway, the lungs, and the 
muscles of respiration. The airway, which includes the nose, mouth, pharynx, larynx, 
trachea, bronchi, and bronchioles, carries air between the lungs and the body‟s exterior. 
The lungs act as the functional units of the respiratory system by passing oxygen into the 
body and carbon dioxide out of the body. Finally, the muscles of respiration, including 
the diaphragm and intercostal muscles, work together to act as a pump, pushing air into 
and out of the lungs during breathing. 
       Generally, the Respiratory tract is divided into two parts  
1. Upper respiratory tract and 
2. Lower respiratory tract. 
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Upper Respiratory Tract 
              The upper respiratory tract, can refer to the parts of the respiratory system lying 
above the sternal angle above the vocal folds, or above the cricoid cartilage. It includes 
the nose and nasal passages, paranasal sinuses, the pharynx, and the portion of the larynx 
above the vocal cord. The larynx is sometimes included in both the upper and lower 
airways.  
Lower Respiratory Tract 
                The lower airways or lower respiratory tract includes the portion of the larynx 
below the vocal folds, trachea, bronchi and bronchioles. The lungs can be included in the 
lower respiratory tract or as separate entity and include the respiratory bronchioles, 
alveolar ducts, alveolar sacs, and alveoli. 
3.2.2 ANATOMY OF UPPER RESPIRATROY TRACT 
3.2.2.1 Nose 
         The Nose is the only externally visible part of the respiratory system. Protruding 
prominently from the face, the nose serves as a vent for air exchange. The structures of 
the nose are divided into the External nose and the Internal nasal cavity. The external 
nose consists of a supporting framework of bone and hyaline cartilage covered with 
muscle and skin. The external openings of the nose, the external nostrils, are bounded 
laterally by the flared alae.         
3.2.2.2 Nasal Cavity 
The Nasal Cavity lies in and posterior to the external nose. During breathing, air enters 
the nasal cavity by passing through the external nares. The nasal cavity is divided equally 
into right and left halves by a midline nasal septum. The nasal cavity is continuous 
posteriorly with the nasal portion of the pharynx through the internal nares, also called 
the posterior nares or choanae. The portion of the nasal cavity just superior to the nostrils, 
called the vestibule, is lined with skin containing sebaceous and sweat glands and 
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numerous hair follicles. The hairs, or vibrissae filter coarse particles (lint, dust, pollen) 
from inspired air.   
 Therefore, the nose       1. Provides an airway for respiration  
   2. Moistens and warms entering air  
   3. Filters inspired air and cleanses it of foreign matter 
   4. Serves as a resonating chamber for speech, and 
   5. Houses the olfactory (smell) receptors 
3.2.2.3 Paranasal Sinuses 
The Paranasal Sinuses are air-filled cavities located within the bones of the face and 
around the nasal cavity and eyes. Each sinus is named for the bone in which it is located. 
 Maxillary sinus- one sinus located within the bone of each cheek  
 Ethmoid sinus- located under the bone of the inside corner of each eye, this is 
really a honeycomb-like structure of 6-12 small sinuses that is better appreciated 
on CT scan images through the face. 
 Frontal- one sinus per side, located within the bone of the forehead above the 
level of the eyes and nasal bridge 
 Sphenoid- one sinus per side, located behind the ethmoid sinuses; the sphenoid is 
not seen in a head-on view but is better appreciated looking at a side view 
3.2.2.4 Mouth 
The Mouth, also known as the oral cavity, is the secondary external opening for 
the respiratory tract. Most normal breathing takes place through the nasal cavity, but the 
oral cavity can be used to supplement or replace the nasal cavity‟s functions when 
needed. Because the pathway of air entering the body from the mouth is shorter than the 
pathway for air entering from the nose, the mouth does not warm and moisturize the air 
entering the lungs as well as the nose performs this function. The mouth also lacks the 
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hairs and sticky mucus that filter air passing through the nasal cavity. The one advantage 
of breathing through the mouth is that its shorter distance and larger diameter allows 
more air to quickly enter the body. 
3.2.2.5 Pharynx 
Pharynx is also known as the throat. The pharynx is a funnel-shaped 
fibromuscular tube that conducts air from the nasal cavity to the larynx. The pharynx 
resembles a short length of garden hose and extends about 5 inches from the base of the 
skull to the level of the sixth cervical vertebra. 
Based on location, The pharynx is divided into 3 regions  
1. Nasopharynx,  
2. Oropharynx, and  
3. Laryngopharynx. 
Nasopharynx 
Nasopharynx is the superior region of the pharynx lying posterior to the nasal 
cavity and connected to the cavity through posterior nares or choanae. It serves only as an 
air passageway. The lining epithelium of nasopharynx is the same pseudostratified 
columnar ciliated type. Goblet cells in the epithelium secrete mucus, which further 
cleans, warms, and moistens incoming air before it moves deeper into the respiratory 
tract.  
Oropharynx 
The oral part of the pharynx is called oropharynx lies posterior to the oral cavity. 
It extends inferiorly from the soft palate to the epiglottis. Given this location, both 
swallowed food and inhaled air pass through it. The oropharynx is lined with a more 
protective epithelium that is non-keratinized stratified squamous type. 
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Laryngopharynx 
The laryngopharynx is the posterior most portion of the pharynx, reaching from 
the hyoid to the cricoid cartilage. The laryngopharynx also serves as a common pathway 
for food and air. It lies directly posterior to the upright epiglottis and extends to the 
larynx, where the respiratory and digestive pathways diverge. 
3.2.2.6 Larynx 
The larynx, also known as the voice box, is a short section of the airway that 
connects the laryngopharynx and the trachea. The larynx is located in the anterior portion 
of the neck, just inferior to the hyoid bone and superior to the trachea. Several cartilage 
structures make up the larynx and give it its structure. The epiglottis is one of the 
cartilage pieces of the larynx and serves as the cover of the larynx during swallowing. 
Inferior to the epiglottis is the thyroid cartilage, which is often referred to as the Adam‟s 
apple as it is most commonly enlarged and visible in adult males. Inferior to the thyroid 
cartilage is the ring-shaped cricoid cartilage which holds the larynx open and supports its 
posterior end. In addition to cartilage, the larynx contains special structures known as 
vocal folds, which allow the body to produce the sounds of speech and singing. The vocal 
folds are folds of mucous membrane that vibrate to produce vocal sounds. The tension 
and vibration speed of the vocal folds can be changed to change the pitch that they 
produce. 
3.2.3 UPPER RESPIRATORY TRACT INFECTIONS 
URTI range from common cold typically a mild self-limited catarrhal syndrome 
of nasopharnyx to life threatening illnesses such as epiglotitis.  
   URTI is specifically manifested as cough, fever, Rhinitis, Pharyngitis, 
Epiglottis, Laryngitis and Tracheitis.              
3.2.4 PHARYNGITIS 
Pharyngitis is typically a type of upper respiratory tract infection. Pharyngitis is 
inflammation of the back of the throat or the pharynx. . It is usually associated with 
viruses or streptococcus pyogenes. But the majority of the cases of acute pharyngitis are 
caused by viruses. It is most common in school going age group children during the 
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winter months. Approximately 40-60% of cases of sore throat are caused by a virus and 
about 15% are associated with streptococcal infection. Uncommon causes include other 
bacteria such as gonorrhea, fungus, irritants such as smoke, allergies, and 
gastroesophageal reflux disease.  
Classification 
It may be classified as acute or chronic.  
 Acute pharyngitis may be catarrhal, purulent or ulcerative, depending on the 
causative agent and the immune capacity of the affected individual.  
 Chronic pharyngitis may be catarrhal, hypertrophic or atrophic. 
3.2.5 CAUSES 
 A wide variety of organism causes acute pharyngitis. The relative importance of 
the different pathogens can only be estimated. Since significant proportion of cases 
(30%) have no identified causes.  
Respiratory viruses are the most common identifiable cause of acute pharyngitis, 
with rhinoviruses (20% of cases) and Corona viruses(at least 5%) accounting for a large 
proportion. Influenza virus, parainfluenza virus, and adenovirus also account for a 
measurable share of cases. Other important but less common viral cause include herpes 
simplex virus (HSV) type 1 and 2, Coxsacki virus A, Cytomegalovirus (CMV), and 
Epstein- Barr virus (EBV). Acute HIV infection can present as acute pharyngitis and 
should be considered in high risk population. 
Acute bacterial pharyngitis is typically caused by streptococcus pyogens which 
accounts for 5-15% of all cases of acute pharyngitis in adults; rates vary depending on the 
season and on health care system utilization. Streptococci of groups C and G account for 
minority cases, although these serogroups are nonrheumatogenic.  
The remaining cause of acute pharyngitis are seen infrequently(<1% each)  but 
should be considered in appropriate exposure groups because of the severity of illness if 
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left untreated; these etiogenic agents include Neisseria gonorroeae, Cornybacterium 
diphtheria, Cornybacterium ulcerans, Yersinia enterocoitica. and Treponema pallidum. 
3.2.5.1 Viral causes 
Viral pharyngitis can be caused by numerous viruses and occur as part of 
common cold and influenza syndrome. These comprise about 40–80% of all infectious 
cases and can be a feature of many different types of viral infections.  
Adenovirus 
In children, Adenovirus causes uncomplicated pharyngitis (most commonly 
caused by adenovirus types 1-3 and 5) or pharyngoconjunctival fever. The latter is 
characterized by fever, sore throat, and conjunctivitis. Unlike rhinovirus infections, 
adenovirus directly invades the pharyngeal mucosa, as shown by the viral cytopathic 
effect. 
 Rhinovirus 
More than 100 different serotypes of rhinovirus cause approximately 20% of 
cases of pharyngitis and 30-50% of common colds. These viruses enter the body through 
the ciliated epithelium that lines the nose, causing edema and hyperemia of the nasal 
mucous membranes. This condition leads to increased secretory activity of the mucous 
glands; swelling of the mucous membranes of the nasal cavity, eustachian tubes, and 
pharynx, and narrowing of nasal passages, causing obstructive symptoms. Bradykinin 
and lysyl-bradykinin are generated in the nasal passages of patients with rhinovirus colds, 
and these mediators stimulate pain nerve endings. The virus does not invade the 
pharyngeal mucosa. Transmission occurs by large particle aerosols or fomites. 
 Epstein-Barr Virus 
Epstein-Barr Virus (EBV) is the causal agent of infectious mononucleosis. EBV 
usually spreads from adults to infants. Among young adults, EBV spreads through saliva 
and, rarely, through blood transfusion. In addition to edema and hyperemia of the tonsils 
and pharyngeal mucosa, an inflammatory exudate and nasopharyngeal lymphoid 
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hyperplasia also develop. Pharyngitis or tonsillitis is present in about 82% of patients 
with infectious mononucleosis.  
Herpes Simplex Virus 
Herpes Simplex Virus (HSV) types 1 and 2 cause gingivitis, stomatitis, and 
pharyngitis. Acute herpetic pharyngitis is the most common manifestation of the first 
episode of HSV-1 infection. After HSV enters the mucosal surface, it initiates replication 
and infects either sensory or autonomic nerve endings. The neurocapsid of the virus is 
intra-axonally transported to the nerve cell bodies in the ganglia and contiguous nerve 
tissue. The virus then spreads to other mucosal surfaces through centrifugal migration of 
infectious virions via peripheral autonomic or sensory nerves. This mode of spread 
explains the high frequency of new lesions distant from the initial crop of vesicles 
characteristic of oral-labial HSV infection. It can cause multiple mouth ulcers. 
 Influenza Virus 
Pharyngitis and sore throat develop in about 50% of the patients with Influenza A 
and in a lesser proportion of patients with influenza B. Severe pharyngitis is particularly 
common in patients with type A. The influenza virus invades the respiratory epithelium, 
causing necrosis, which predisposes the patient to secondary bacterial infection. 
Transmission of influenza occurs by aerosolized droplets  
Para Influenza Virus 
Pharyngitis caused by Para Influenza Virus types 1-4 usually manifests as the 
common cold syndrome. Parainfluenza virus type 1 infection occurs in epidemics, mainly 
in late fall or winter, while parainfluenza virus type 2 infection occurs sporadically. 
Parainfluenza virus type 3 infection occurs either epidemically or sporadically. 
 Coronavirus 
Pharyngitis caused by Coronavirus usually manifests as the common cold. As in 
rhinovirus colds, viral mucosal invasion of the respiratory tract does not occur. 
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Enterovirus 
The major groups of Enteroviruses that can cause pharyngitis 
are coxsackievirus and echovirus. Although enteroviruses are primarily transmitted by 
the fecal-oral route, airborne transmission is important for certain serotypes. Enteroviral 
lesions in the oropharyngeal mucosa are usually a result of secondary infection of 
endothelial cells of small mucosal vessels, which occurs during viremia following 
enteroviral infection in the GI tract. 
Respiratory Syncytial Virus 
Transmission of Respiratory Syncytial Virus (RSV) occurs by fomites or large-
particle aerosols produced by coughing or sneezing. Immunologic mechanisms may 
contribute to the pathogenesis of the severe disease in infants and elderly patients.   
Cytomegalovirus 
Acute acquired Cytomegalovirus (CMV) infection is transmitted by sexual 
contact, in breast milk, via respiratory droplets among nursery or day care attendants, and 
by blood transfusion. Infection in the immune-competent host rarely results in clinically 
apparent disease. Infrequently, immuno-competent hosts exhibit a mononucleosis like 
syndrome with mild pharyngitis. 
 Human Immuno deficiency Virus 
Pharyngitis develops in patients infected with Human Immuno deficiency Virus 
(HIV) as part of the acute retroviral syndrome, a mononucleosis like syndrome that is the 
initial manifestation of HIV infection in one half to two thirds of recently infected 
individuals. 
Epidemiology 
In United States each year, Viral pharyngitis is responsible for more than 40 
million visits to health care providers. Most children and adults experience 3-5 viral 
upper respiratory tract infections (including pharyngitis) per year. 
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Mortality 
Worldwide, viral pharyngitis is one of the most common causes of absence from 
school or work. The National Ambulatory Medical Care Survey showed that upper 
respiratory tract infections, including acute pharyngitis, accounted for 200 annual visits to 
a physician per 1000 population between 1980-1996.  
Sex 
Viral pharyngitis affects both sexes equally. 
Age 
Viral pharyngitis affects both children and adults, but it is more common in 
children.  
 
3.2.5.2 Bacterial Cause 
A number of different bacteria can infect the human throat. The most common 
and important bacterial cause of pharyngitis is Streptococcus pyogenes(group 
A Streptococcus [GAS]) but others include Streptococcus pneumoniae, Haemophilus 
influenzae, Bordetella pertussis, Bacillus anthracis, Corynebacterium diphtheriae, 
Neisseria gonorrhoeae, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. 
When suspected, bacterial pharyngitis should be confirmed with routine diagnostic tests 
and treated 
Streptococcal Pharyngitis 
Streptococcal pharyngitis or strep throat is caused by group A beta-hemolytic 
streptococcus (GAS). It is the most common bacterial cause of cases of pharyngitis (15–
30%). Common symptoms include fever, sore throat, and large lymph nodes. It is a 
contagious infection, spread by close contact with an infected individual. A definitive 
diagnosis is made based on the results of a throat culture. 
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Fusobacterium Necrophorum 
Fusobacterium Necrophorum is a normal inhabitant of the oropharyngeal flora 
and can occasionally create a peritonsillar abscess. In 1 out of 400 untreated cases, 
Lemierre's syndrome occurs. 
Diphtheria 
Diphtheria is a potentially life-threatening upper respiratory infection caused by 
Corynebacterium diphtheriae which has been largely eradicated in developed nations 
since the introduction of childhood vaccination programs, but is still reported in the Third 
World and increasingly in some areas in Eastern Europe. Antibiotics are effective in the 
early stages, but recovery is generally slow. 
Epidemiology 
Acute pharyngitis caused by bacteria accounts for approximately 12 million 
annual ambulatory care visits in the United States. It ranks within the top 20 most-
common primary diagnosis groups.  
In temperate climates, GAS pharyngitis occurs most commonly in the winter and 
early spring.  
International an estimated 616 million cases of GABHS pharyngitis occur 
annually worldwide. Rheumatic heart disease, which may be a consequence of GABHS 
pharyngitis, is estimated to cause about 6 million years of life lost annually. The burden 
of rheumatic heart disease disproportionately affects populations from developing 
countries. In terms of estimated global mortality, GABHS is one of the top 10 pathogens, 
behind HIV infection and malaria and ahead of tetanus and pertussis. 
Mortality 
Although GABHS pharyngitis is usually a self-limited entity, on average, a single 
episode in a child results in 1.9 days absence from school and a parent missing 1.8 days 
from work to care for the child. Children with GABHS pharyngitis experience symptoms 
for an average of 4.5 days. 
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Sex 
GABHS pharyngitis has no sexual predilection. 
Age 
GABHS pharyngitis is most common in individuals aged 5-15 years, although 
adults may also acquire the disease. Streptococcal pharyngitis is very uncommon in 
children younger than 3 years with the exception of children with risk factors such as an 
older close or household contact with GAS infection. Acute rheumatic fever is also rare 
in children younger than 3 years and in adults.  
3.2.5.3 Fungal 
Some cases of pharyngitis are caused by fungal infection such as Candida 
albicans causing oral thrush. 
3.2.5.4 Non-Infectious 
Pharyngitis may also be caused by mechanical, chemical or thermal irritation, for 
example cold air or acid reflux. Some medications may produce pharyngitis such as 
pramipexole and antipsychotics. 
3.2.5.5 Others 
    A few other causes are rare, but possibly fatal, and include parapharyngeal space 
infections: peritonsillar abscess, submandibular space infection (Ludwig's angina), and 
epiglottitis. 
3.2.6 MODE OF TRANSMISSION 
GABHS is spread from person to person through large droplet 
nuclei.
 
Consequently, close quarters (eg- barracks, daycares, and dormitories) facilitate 
transmission.  
In temperate regions, the prevalence of GABHS infection increases in the colder 
months, presumably because of the tendency of people to congregate indoors. 
 Spread within families is common. The risk of acquiring GABHS from an 
infected family member is 40%, and nearly one in four of infected individuals eventually 
exhibit symptoms. Twenty-four hours after appropriate antibiotics are initiated, the 
patient is no longer considered contagious. 
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3.2.7 PATHOPHYSIOLOGY  
In viral pharyngitis, viruses gain access to the mucosal cells lining the 
nasopharynx and replicate in these cells. Damage to the host is often caused by damage to 
the cells where the viruses are replicating. 
In bacterial pharyngitis, .S pyogenes, which contains group A antigens and 
displays beta-hemolysis, is the most common species referred to as a group A beta-
hemolytic streptococci (GABHS). Beta-hemolytic streptococci have the ability to cause 
large zones of hemolysis on blood agar.    
 S pyogenes attaches to the mucosal epithelial cells using M protein, lipoteichoic 
acid, and fibronectin-binding protein (protein F).  It has a capsule composed of 
hyaluronic acid that prevents phagocytosis by host macrophages; because the hyaluronic 
acid in the bacterial capsule is identical to host hyaluronic acid. The capsule facilitates 
bacterial survival by covering the bacterial antigens. Extracellular factors produced by S 
pyogenes during the infection include protease and hyaluronidase. These extracellular 
factors assist the bacteria in invading the mucosa. An autoimmune reaction occurs in 
some patients following production of an immune response to these cross-reactive 
bacterial antigens and damages the patient‟s heart or kidneys. 
The most important virulence factor of GABHS is the M protein. This protein, 
located peripherally on the cell wall, is required for invasive infection. T cells exposed to 
this M protein are postulated to cross-react with similar epitopes on human cardiac 
myosin and  laminin, contributing to the pathogenesis of rheumatic heart disease 
GABHS contains a hyaluronic acid capsule, which also plays an important role in 
infection.
  
Bacteria that produce large quantities of this capsule exhibit a characteristic 
mucoid appearance on blood agar and may be more virulent. 
Certain GABHS exotoxins act as superantigens by up-regulating T cells.
 
These 
super    antigens can prompt a release of proinflammatory  cytokines and may synergize 
with lipopolysaccharide. It has been speculated that these superantigens evade the 
pharyngeal immune response, resulting in proliferation of GABHS while permitting 
immune-mediated elimination of commensal organisms. 
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Adhesins enable GABHS attachment at sites such as the pharynx. This attachment 
allows for colonization and competition with normal host flora. 
Some strains produce erythrogenic exotoxins (A, B and C) which cause the rash 
of scarlet fever in susceptible hosts. 
3.2.8 SYMPTOMS 
Symptoms of pharyngitis may include the following: 
 Sore throat 
 Fever 
 Headache 
 Joint pain and muscle aches 
 Skin rashes 
 Swollen lymph glands in the neck 
Sore throat with cold: 
 Sneezing 
 Cough 
 A low fever (less than 102 degrees F) 
 Mild headache 
Sore throat with flu: 
 It present with rapid onset high temperature >102 degrees F 
  headache  
 Fatigue 
 Chills 
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        Normal mouth 
Viral phar       
    Strep throat 
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Sore throat with mononucleosis: 
 Enlarged lymph nodes in neck and armpits 
 Prominent  tonsillar enlargement with exudate 
 Headache 
 Loss of appetite 
 Hepatosplenomegaly 
 Rash 
 Generalized fatigue 
Strep throat, another type of pharyngitis, can also cause: 
 Rapid with prominent sore throats 
 Headache and gastrointestinal symptom (Abdominal pain, vomiting) are frequent. 
 difficulty in swallowing 
 red throat  and tonsils are  enlarged and covered with  white or gray patches 
 Anterior cervical  lymph nodes are enlarged and tender 
 No fever and cough 
 loss of appetite 
 nausea 
 unusual taste in the mouth 
 general malaise 
Adenopharyngitis: 
 It may produce concurrent cojuctivitis and fever (Pharyngocojuctival fever)  
 Typically the degree of neck lymph node enlargement is modest.   
 The throat often does not appear red, although it is painful.   
Coxsackivirus pharyngitis:  
It may produce small (1-2mm) grayish vesicles and punched out ulcers in the 
posterior pharynx or small (3-6mm) yellowish- white nodules in the posterior 
pharynx(Acute lymphonodular pharyngitis. 
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3.2.9 PHYSICAL EXAMINATION 
Temperature 
 Fever is usually absent or low-grade in viral pharyngitis. 
Head, ears, eyes, nose, and throat 
 Conjunctivitis may be seen in association with adenovirus. 
 Scleral icterus may be seen with infectious mononucleosis. 
 Tonsillopharyngeal/palatal petechiae are seen in GAS infections. 
 Oropharyngeal vesicular lesions are seen in coxsackievirus and Herpes virus. 
3.2.10 COMPLICATION 
Complications of the GABHS infection may result in  
     1. Suppurative or  
     2. non-suppurative  
More common suppurative infections include  
 retropharyngeal abscess  
 peritonsillar abscess  
 sinusitis 
 cervical lymphadenitis 
 otitis media  
 mastoiditis 
 Epiglottitis 
 Thyroiditis 
Non suppurative infections 
Acute rheumatic fever  
This disorder usually occurs 2-4 weeks after an episode of pharyngitis. 
Administration of proper antibiotics up to 9 days after the onset of pharyngeal symptoms 
has been shown to prevent this manifestation. Acute rheumatic fever is reported to result 
from one of every 400 untreated GABHS infections
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Rheumatic heart disease  
This is the chronic valvular manifestation of acute rheumatic fever. The mitral 
valve is the site most often affected, and either regurgitation or stenosis may result.
 
In 
individuals with rheumatic heart disease, long-term secondary prophylaxis, often with 
benzathine penicillin, decreases the risk of subsequent episodes of acute rheumatic fever 
and further heart damage. 
Poststreptococcal glomerulonephritis  
This usually occurs 1-3 weeks following GABHS pharyngitis. Poststreptococcal 
glomerulonephritis, which may also follow a GABHS skin infection, has not been shown 
to be preventable with proper administration of antibiotics. Patients often present with 
hematuria, edema, and hypertension.  
3.2.11 DIAGNOSTIC TEST 
GABHS rapid antigen detection test 
This is the preferred method for diagnosing GAS infection in the emergency 
department because of difficulties with culture follow-up.  
Only patients with a high clinical likelihood of GAS pharyngitis should be tested. 
Antigens are specific, but sensitivities vary. The sensitivity of the GABHS rapid antigen 
detection test is 70-90%, and the specificity is 90-100%, depending on the manufacturer. 
 
Children with a negative antigen test should have a follow-up culture unless the 
antigen being used in the office has been shown to be as sensitive as a culture.
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The use of a GABHS rapid antigen detection test can decrease the use of 
unnecessary antibiotics in pediatric patients when used properly. 
Adults do not need follow-up culture after a negative antigen test because of the 
low incidence of GAS in this population.
 
 
Throat culture 
This is the criterion standard for diagnosis of GAS infection (90-99% sensitive). 
Although less expensive than the rapid antigen detection test, it is not be the best test to 
use in the emergency department because of difficulty with follow-up. The guidelines 
that recommend cultures for GAS screening are aimed at office-based practices and not 
the emergency department. 
Patients can be treated up to 9 days after onset of symptoms to prevent acute 
rheumatic fever, so immediate antibiotic therapy is not crucial if patients can be easily 
contacted for follow-up should a culture become positive.
 
 
Other 
Additional tests include the following: 
 Mono spot is up to 95% sensitive in children (less than 60% sensitivity in infants) 
 Peripheral smear may show atypical lymphocytes in infectious mononucleosis 
 Perform gonococcal culture as indicated by history 
 A complete blood count (CBC) 
 erythrocyte sedimentation rate (ESR) 
  C-reactive protein have a low predictive value and usually are not indicated  
3.2.12 RISK FACTORS FOR PHARYNGITIS 
 Cold and flu seasons 
 Having close contact with someone who has a sore throat or cold 
 Exposure to secondhand smoke 
 Frequent sinus infections 
 Allergies 
 Attending daycare or crowded schools 
 Air conditioning 
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 Chronic cough 
 Hoarse voice 
 Living in a hot, dry climate 
 Reflux esophagitis 
 Any condition that weakens the immune system, such as: Organ transplant 
 Chemotherapy: the administration of medicines that kill cancer cells.  
3.2.13 DIET FOR PHARYNGITIS 
 The following remedies may help soothe a sore throat: 
 Getting rest 
 Drinking warm liquids, such as lemon tea or tea with honey 
 Gargling with warm salt water (1/2 tsp of salt in 1 cup of water) throughout the 
day 
 Running a cool-mist vaporizer or humidifier 
 Drinking plenty of fluids to prevent dehydration 
 Eating warm broth 
3.2.14 PREVENTION OF PHARYNGITIS 
Maintaining proper hygiene can prevent many cases of pharyngitis. 
 avoid sharing food, drinks, and eating utensils 
 avoid individuals who are sick 
 Wash your hands often, especially before eating and after coughing or sneezing 
nose or after caring for a child with a sore throat. 
 Use alcohol-based hand sanitizers when soap and water aren‟t available 
 Avoid inhaling secondhand smoke 
 If a toddler with pharyngitis has been chewing or sucking on toys, wash these 
objects thoroughly in water and disinfectant soap, then rinse well. 
 Promptly dispose of any dirty tissues from runny noses and sneezes, and then 
wash your hands. 
 Avoid caffeinated products.  
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3.3. DRUG REVIEW 
3.3.1. tpy;tk; (Aegle marmelos.Linn, corr) 
Eng. Name  : Bael (tree) Holy fruit free 
Sans   : Bilva 
Family Name  : Rutaceae 
Part used  : Leaf, flower, ripe and unripe fruit, root bark, root, gum 
Suvai   : Astringent 
Thanmamai  : Thatpam 
Pirivu   : Veppam 
        ACTIONS:   
            Leaves              : Diaphoretic 
                                     Aphrodisiac 
                                     Febrifuge 
            Flower, Unripe fruit   : Astringent  
                                               Stomachic 
                                               Digestive 
        Fruit              :  Laxative  
                                       Astringent  
                                               Stomachic 
            Root, Resin             : Aphrodisiac 
          Pulp              : Stimulant  
                        Antipyretic 
                        Antiscorbutic 
         Leaf juice             : Bitter and pungent          
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GENERAL CHARECTERS 
  tpy;Ytj;jpd; NtUf;F tPWFd;k thAfgk; 
  nrhy;nyhzh gpj;je; njhlh;Nrhig – tyfg 
  jhfRuk; ePNuw;;wQ; re;epnahL nka;typAk; 
  NtfnkhL ePq;FNk. 
mf;fdp ke;jk; mNuhrpe;jp rhuk;tpf;fy; 
epw;fhpa gpj;jRuk; ePs;the;jp - Rl;fNeha; 
Mjpa Neha; VFk; moNfhL G\;bAz;lhk; 
Nfhjpy;tpy;t Ntujidf; nfhs;. 
tpy;t jsph;- vy;yh Nkfj;ijAk;> G+- ke;jj;ijAk;> gpQ;R- Fd;kj;ijAk;> 
gok;- fz;zpUisAk;> gprpd;- nte;ePh; FiwitAk;> ,iy- Ruj;ijAk;> %f;FePh; 
gha;jiyAk; ePf;Fk;. 
CHEMICAL CONSTITUENTS 
            Leaves  :  Aegeline 
                                     Aegelenine 
                               Flavan -3-ols,  
                                Sitosterol  
                   Essential oil,  
                   Marmilosin, 
                   Reducing sugar 
            Root   : Marmin,  
                            Auraptene,  
                            Lupeol 
      Fruit   : Xanthotoxol,  
                            Coumarins Scoparine,  
                            Scopoletin, 
                            Marmilosin  
                             Tannic Acid,  
                            Mucilage and Pectin 
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RESENT RESEARCH STUDIES ON AEGLE MARMELOS 
1. Studies on the anti-inflammatory, antipyretic and analgesic properties of the 
leaves of Aegle marmelos Corr. 
Journal of Ethnopharmacology 
Veerappan Arul, Shigeru Miyazaki, Renganathan Dhananjayan 
Reference: 
http://www.sciencedirect.com/science/article/pii/S0378874104004441 
2. Evaluation of the anti-inflammatory activity of Aegle marmelos(Bilwa) root 
Indian Journal of pharmacology  
Jyoti M.Benni, M.K.Jayanthi and R.N.Suresha 
Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153700/ 
3. Evaluation of the anti-inflammatory activity of hydroalcoholic extract of aegle 
marmelos leaves 
Jaganmohan Chandran, Parthiban.S Shanmugam, T Tamizhmani 
Reference:https://www.researchgate.net/publication/263966707_evaluatio
n_of_the_antinflammatory_activity_of_hydroalcoholic_extract_of_aegle_
marmelos_leaves 
4. Evaluation of Aegle marmelos (Bael) for Anti-inflammatory Activity in Rats 
Ghangale G. R., Surve V. S., Anbarasan K., Gatne M. M. 
Reference:http://www.indianjournals.com/ijor.aspx?target=ijor:jbvc&volu
me=16&issue=1&article=006 
5. Evaluation of antidiarrhoeal and antiinflammatory activity of Aegle marmelos 
on albino wistar rats  
Pelagia Research Library European Journal of Experimental Biology, 
2016, 6(2):26-29 ISSN: 2248 –9215 CODEN (USA): EJEBAU  
(D. Vijay Anand Raju, V. Sandhya, M. Vineel Chandra, M. Muralidhar 
Reddy and Bolay Bhattacharya) 
Reference:http://www.imedpub.com/articles/evaluation-of-antidiarrhoeal-
and-antiinflammatory-activity-of-iaegle-marmelosi-on-albino-wistar-
rats.pdf 
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 6.  Immunomodulatory Potential of Methanol Extract of Aegle marmelos in Animals 
Indian Journal of Pharmaceutical Sciences 
Indian J Pharm Sci. 2011 Mar-Apr; 73(2): 235–240. 
(H V Govinda and S. M. B. Asdaq) 
Reference:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267313/ 
 
3.3.2 mThp (Indigofera tinctoria, Linn) 
Eng. Name  : Indian Indigo plan 
Sans   : Nilini 
Family Name  : Fabaceae 
Part used  : Leaf, root 
Suvai   : Bitter 
Thanmai  : Veppam 
Pirivu   : Acrid 
            ACTIONS  : Germicide 
     Antiperiodic 
     Stimulant 
GENERAL CHARACTERS 
chpayT hpj;jioj;jhd; XJ gjpndz; 
mhpaeQ;irj; jpd;wth;f;Fk; MFk; - njhpthpa 
thjntg;G fhkhiy ike;jh; FWkhe;jQ; 
rPjk; mfw;We; njhp. 
rd;dp gjp%d;WQ; re;njhbj;j thjKjy; 
cd;D tplf;fbAk; XLq;fhz; - kpd;Dq; 
fThpepwk; cz;lhFq; fhrpdpAs; ey;y 
mtphpapiy jd;dhy; mwp. 
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CHEMICAL CONSTITUENTS 
 Indican (a glucoside) 
 Indigotin or Indigo- blue 
 Luc- Indigo or Indigo White 
 Tannins 
 Terpinoids 
 Flavinoids 
 Apigenin 
 Kaempferol 
 Luteolin 
 Quercetin 
 Indicaine 
 6,6‟-dibromoindigotine 
 Deguelin 
RESENT RESEARCH STUDIES ON INDIGOFERA TINCTORIA 
1. Anti-Bacterial, Anti-Oxidant and Cytotoxicity effect 
            Renkadevi K.P et al.,(2011) study has been under taken with an objective to 
determine the antibacterial, anti-oxidant and cytotoxic activity of the leaf extract of 
indigofera tinctoria. Anti-bacterial activity was carried out on in vitro lung cancer cell 
line. The extract screened for phyto chemical analysis was found to contain bioactive 
compounds like falvonoid, saponins, tannins, steroidal terpens, phenols and 
anthroquinone were identified by GC -MS analysis.  
The leaf extract I.tinctoria having the ability to inhibit the growth of gram positive 
bacteria namely Staphylococcus aureus, Bacillus pumilus and Streptococcus pyrogens 
and zone of inhibition was observed 16 and 17 mm, respectively but not shown growth of 
inhibition on gram negative bacteria Escherichia and pseudomonas aeruginosa. Strong 
antioxidant activity was observed both qualitatily and quantitatively. The strong 
antioxidant was observed at 250ugml-1 with an IC 50 value of 51.66 which is higher than 
that of standarad ascorbic acid. The cytotoxic effect of I.tinctoria leaf extract on lung 
cancer cell line NCI-H69 was studied. The percentage cell viability of cells was found to 
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decrease at increasing concentration. GC-MS analysis of the leaf extract shows 6 
compounds. This study suggests that ethanol extract of Indigofera tinctoria have profound 
antibacterial, antioxidant and cytotoxic effect. 
2. Anti –Inflammatory effect 
    Pramodm K.Tyagi et al., (2010) elucidate the anti-inflammatory activity of 
ethanolic extract of I.tinctoria leaves (500 & 100 mg/kg ).When compare to control as 
well as positive control Ibuprofen (Standard drug ) group values are expressed as mean 
and SD. Statistical significance was determinded using the student‟s t-test. Values with 
p<0.01 were considered significance. the present study indicated that oral administration 
of ethanol extract of I.tinctoria linn dose dependently improve the potent anti-
inflammatory activity. The extact lowers the carrageen an induced rat paw oedema. 
Further pharmacological and biochemical investigations are essential to elucidate the 
mechanism of action.  
 Review Paper Indigofera tinctoria Linn - A Phytopharmacological Review 
International Journal of Research in Pharmaceutical and Biomedical Sciences 
ISSN: 2229-3701  
(Saraswathi Motamarri N, Karthikeyan M, Rajasekar S and Gopal) 
Reference:https://www.doc-developpement-durable.org/file/Culture-plantes-
colorantes/FICHE_PLANTES/indigo/Indigotier/Indigofera%20tinctoria%20Linn
%20-%20A%20Phytopharmacological%20Review.pdf 
 3. Preliminary phytochemical screening and Evaluation of Anti-inflammatory activity 
of Ethanolic extract of leaves of Indigofera tinctoria Linn 
(B. R.Sarkar, V. K. Rai, B. Kapoor, S. Sharma, J.P. Mohanty, D. Sarkar,  
M.K.Sharma, A. Kar)  
Reference:https://www.researchgate.net/publication/262732289_Preliminary_phy
tochemical_screening_and_Evaluation_of_Anti_inflammatory_activity_of_Ethan
olic_extract_of_leaves_of_Indigofera_tinctoria_Linn 
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4.  Immunomodulatory Activity of Indigofera Tinctoria Leaf Extract on in Vitro 
Macrophage Responses and Lymphocyte Proliferation 
International Journal of Pharmcy and Pharmaceutical Sciences 
(Madakkannu Boothapandi, Ravichandran Ramanibai) 
Ref: https://innovareacademics.in/journals/index.php/ijpps/article/view/9932 
 
5. Physicochemical and Antioxidant Assays of Methanol and Hydromethanol Extract 
of Ariel Parts of Indigofera tinctoria Linn 
Indian journal of Pharmaceutical sciences.  
Indian J Pharm Sci. 2015 Nov-Dec; 77(6): 729–734 
(Veena Sharma and Aastha Agarwal) 
Ref:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778233/ 
 
6.Determination of Anti- Bacterial Anti-Oxidant and Cytotoxicity effect of Indigofera 
tinctoria on Lung cancer cell line NCI – h69.  
Internationa journal of pharmacology 7(3):356-362, 2011 
(K.P.Renukadevi and S.Suhani Sultana) 
Ref;http://docsdrive.com/pdfs/ansinet/ijp/2011/356-362.pdf 
 
3.3.3 ntq;fhak; (Allium cepa.Linn) 
Eng. Name  : Onion 
Sans   : Pallandu 
Family Name  : Alliaceae 
Part used  : Seeds, flower, Bulb 
Suvai   : Bitter 
Thanmai  : Veppam 
Pirivu   : Acrid 
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     ACTIONS  : Stimulant 
  Diuretic 
       Expectorant 
       Emmenagogue 
        Rubefacient 
      Demulsent 
      Aphrodisiac  
GENERAL CHARACTERS 
ntg;g% yq;fpue;jp tPWuj;j gpj;jKld; 
nrg;Geh mf;fue;jP uhj;jhfk; - ntg;Gf; 
fLg;gWke; jQ;re;jp fhrk;tapw; Wg;gy; 
jbg;NgWk; ntq;fhaj;jhy;. 
fpoq;F ntq;fhaj;jhy;> clypd; ntg;gk;> %yk;> rpuq;F> FUjpaoy; Neha;> 
mf;fuk;> ePh;Ntl;if> fopr;ry; ,it ePq;Fk;. 
CHEMICAL CONSTITUENTS 
 Quercetin 
 Fructose 
 Quercetin-3-glucoside 
 Flavinoids 
 Flavenols 
 Cycloalliine 
 Thiosulphates 
 Isorhamnetin-4-glucoside 
 Organosulphur compounds 
 Allylsulfides 
 Sulphur and selenium 
 S-alkenyl cysteine sulfoxides. 
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RESENT RESEARCH STUDIES ON ALLIUM CEPA 
1. Evaluation of analgesic and anti-inflammatory effects of fresh onion juice in 
experimental animals 
African Journal of Pharmacy and Pharmacology Vol. 6(23), pp. 1679-
1684, 22 June, 2012 
(Sima Nasri , Mahdieh Anoush,  Narges Khatami) 
Reference:http://www.academicjournals.org/article/article1380798317_Nasr
i%2520et%2520al.pdf 
 
2. Antibacterial activity of fresh juices of allium cepa and zingiber officinale 
against multidrug resistant bacteria 
International Journal of Pharma and Bio Sciences 
(G.O.Adeshina, S.Jibo, V.E.Agu, J.O.Ehinmidu) 
Reference:http://www.ijpbs.net/download.php?download_file=volume2/issu
e2/bio/28.pdf 
 
3.3.4 fLf;fha; (Terminalia chebula. Retz) 
Eng. Name  : Chebuic Myrobalan, Ink nut 
Sans   : Pathya, Sudha, Bhishak 
Family Name  : Combretaceae 
Part used  : Fruits 
Suvai   : Acrid 
Thanmai  : Veppam 
Pirivu   : Sweet 
ACTIONS:  
 Gentle laxative 
 Astringent 
 Alterative 
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GENERAL CHARACTERS 
  jhil fOj;jf;fp jhY Fwpaplg; 
gPil rpypgjKw; NgjpKlk;-Milnal;lhj; 
J}ykpb Gz;thj Nrhzpfh khiyapud; 
Lhykpb Nghk;tupf;fh ahy;. 
                   - mfj;jpau; Fzthflk;.         
nrhy;Y kupjfpNkw; Nwhiy kJTlNd 
ay;Yk; gfY kapyNt-fy;Yq; 
fiua TunkOg;Gq; farpj;jp Az;lhk; 
eiuAe; jpiuAkpiy ie. 
- Njud;ntz;gh.  
,Uky;> njhz;ilf; fk;ky;> Nfhio ntspg;gLjy;> ,iug;G> ,isg;G> fz; 
Neha;fs;> cjl;L Neha;fs;> jiy Neha;fs;> ePh; Ntl;if> ghz;L> 
Nrhig>ngUtapW> GuhzRuk;> tplRuk;> fgthj Nuhfk;> mrPuzk;> moiy> 
cs;sq;fhy; vhpT> fhkhiy> cl;Ruk;> Njh\k;> nts;is> <uy; Neha;> FUjpaoy;> 
jkuf Neha;> FUkk;> Fl;lk;> %h;r;rhNuhfk;> %yNuhfk;> m];khp> gTj;jpuk;> 
tha;g;Gz; Kjypa Neha;fs; Nehq;Fk;. 
CHEMICAL CONSTITUENTS 
 Tannic acid 
 Gallic acid 
 Chebulinic acid 
 Mucilage 
RESENT RESEARCH STUDIES ON TERMINALIA CHEBULA 
1. Evaluation of in-vitro anti-inflammatory activity of chebulinic acid from 
Terminalia chebula Linn. against the denaturation of protein 
Reference:https://sciforum.net/conference/ecsoc18/paper/2584/download/ 
pdf  (Sima Singh, Uma Ranjan Lal) 
2. Anti-inflammatory acxtivity of constituents isolated from Terminalia chebula 
Reference: https://www.ncbi.nlm.nih.gov/pubmed/25230505  
(Yang MH, Ali Z, Khan IA, Khan SI) 
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3.3.5 rpw;whkzf;;F nea ; (vz;nza;) (Ricinus communis) 
Eng. Name  : Castor-oil 
Sans   : Lahu-Yeranda-tailam 
Family Name  : Euphorbiaceae 
Part used  : Leaf, Root, Seed 
Suvai   : Bitter 
Thanmai  : Veppam 
Pirivu   : Acrid 
ACTIONS: 
             Root bark and Oil : Nonirritant purgative 
             Seeds   : Counter irritant 
             Leaves   : Galactogogue 
  Oil                              :  
 Anti-inflammatory 
 Emollient 
 Anti-infectious  
 Anti-rheumatic 
 Fungicidal 
 Laxative 
 Immune stimulant 
 Insecticidal 
 Anti-viral 
 Anti-allergic  
 Anthelmintic 
 Germicidal 
 Disinfectant  
  Analgesic  
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GENERAL CHARACTERS 
  Mkzf;F nea;ahy; eyKz;lhk; ahth;f;Fk; 
G+kzf;F Nkdp GhpFoNy – tha;kzf;ff; 
nfhs;spy; tapWtpLq; NfhuKs;s thAtWk; 
cs;spy;tU Fd;kk;Ngh NkhJ. 
  mk;nghdpw Kk;tpe;J khq;Flyp Ndw;wkWk; 
Ik;nghwpr; R+nlhpT khWq;fhz; - mk;Gtpapw; 
ghkzf;F kpd;gnkhopg; ghtha;! eyq;nrwpe;j 
Mkzf;F nea;ia mUe;J. 
Mkzf; nfz;nza; jd;id azpepy kwpaf; Nfz;kpd; 
G+kzr; re;JNjhWk; nghUe;jpa thjk; Nghf;Fk; 
jPke;je; jhDk; Nghf;Fe; jpfo;Tld; tpiuT Kz;lhk; 
jPkdf; Flypy; thjQ; Nrhh;Fl Nyw;wk; NghNk. 
 rpw;whkzf;nfz;nza; - kUe;jpd; Ntfk; typapdhy; vUthapYz;lhFk; 
moiy (ePh;r;RUf;F> nts;is) Mfpaitfis ePf;Fk;. 
 Foe;ijfisj; jha;g;Nghy; tsh;f;Fk;. 
 Foe;ijfSf;Fk;> gps;is ngw;w ngz;kzpfSf;Fk; tapW fopaf; 
nfhLj;jw;F> ,/J xU rpwe;j kUe;jhFk;.  
 ,ij iff;Foe;ij> fpo taJilath;> R+y; nfhz;lth;> gps;is ngw;wth;> 
rPjFUjp Ngjpahy; tUe;Jgth; Kjypath;fSf;Fk; mr;rkpd;wpf; 
nfhLf;fyhk;. 
 grpapd;ik tapw;Wtyp ,tw;why; Jd;GWNthUf;Fk; ,ijj; juyhk;.  
 Iaj;jpd; ngUf;fhy;> Nfhiof;fl;L> ,iug;G> ,Uky; ,itfshy; 
<Lgl;lth;fSf;Fk; ,tw;iwf; nfhLf;f tapW fope;J ed;ik cz;lhFk;. 
CHEMICAL CONSTITUENTS 
 Ricin 
 Starch 
 Mucilage 
 Ricinoleste of glycerol or tri-ricinolein 
 Palmitic acid 
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 Stearin 
 Ricinolic acid- 94% 
 Glycerides of dihydroxystearic acid 
 Linoleic acid-0.2% 
 Oleic acid,  
 Stearic acid- 1.0% 
 Linolenic acid- 4.3%  
 Saturated fatty acid- 1.0% 
 Unsaturated fatty acid -98.3 % 
RESENT RESEARCH STUDIES ON CASTOR OIL 
1. Evaluation of Analgesic Activity of Castor Oil in Experimental Animals 
International Journal of Universal Pharmacy and Life Sciences  
              (K.J. Kore, R.V. Shete., M.P.Kabra, R.M.Rachhadiya ) 
2. Effect of ricinoleic acid in acute and subchronic experimental models of 
inflammation. 
               Mediators of Infammation Mediators Inflamm. 2000; 9(5): 223–228 
   (  C Vieira, S Evangelista, R Cirillo, A Lippi, C A Maggi, and S Manzini) 
             Reference:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781768/  
3. Antimicrobial Activity of Castor oil Plants (Ricinus Communis) Seeds Extract 
against Gram Positive Bacteria, Gram Negative Bacteria And Yeast 
(Hashem Rahmati, Saeid Salehi,Abdorrasoul Malekpour and Farzaneh 
Farhangi) 
Internationa Journal of Molecular Medicine and Advance Sciences 11 (1): 
9-12, 2015. ISSN: 1813-176X 
Reference:http://docsdrive.com/pdfs/medwelljournals/ijmmas/2015/9-
12.pdf 
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4. MATERIALS AND METHODS 
4.1 PREPARATION OF THE TRIAL DRUG VILVA ENNAI 
The required plants were collected from patcha malai and raw drugs were 
purchased from raw drug shop and are authenticated by the medicinal botanist 
Dr.D.Aravind MD(S), M.Sc., National Institute of Siddha, Chennai 47. The medicine was 
prepared in Gunapadam lab of National Institute of Siddha after proper purification. The 
prepared medicine was also authenticated by the concerned Head of the Department for 
its completeness.   
Ingredients 
                           Chitramanakku ennai    (Ricinus communis)   - 325 ml 
     Vilva elaicharu             (Aegle marmelos)             - 325 ml 
     Avuricharu                   (Indigofera tinctoria)         - 325 ml 
    Vellai vengayacharu     (Allium cepa)                      - 325 ml 
                            Kadukkaithol               (Terminalia chebula)           - 40 g 
Method of purification 
           All the ingredients mentioned in the formulation are purified as per the direction 
described in the Siddha literature. 
Preparation Method 
 Castor oil (Ricinus communis), juice extracted from the leaves of vilvam (Aegle 
marmelos), avuri (Indigofera tinctoria), and vellai vengayam (Allium cepa) each 325ml 
are taken in a bowl. Add 40gm of powdered kadukkai to the mixture and it is allowed to 
boil until it reaches waxy consistency. Then it is filtered and collected and stored in a 
clean dry glass container. 
Vehicle: Hot water       Dose: 3 ml (OD – morning)  
Indication: All types of Kanam.   Duration: 5 days. 
Drug Storage: Prepared medicine will be stored in clean and dry glass container. 
Dispensing: Given 15 ml Vilva Ennai in air tight container. 
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INGREDIENTS OF VILVA ENNAI 
                
              Aegle marmilos                                   Terminalia chebula        
           
              Allium cepa                                         Indigofera tinctoria       
                                  
                                                                             
                                                          Castor oil 
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  PREPARED TRIAL DRUG – VILVA ENNAI 
    
4.2 PRECLINICAL STUDIES 
4.2.1 In-vitro Anti-Inflammatory Activity 
 The anti-inflammatory activity of the trial drug VILVA ENNAI was done at 
Noble Research Solutions, Sathyabama University, Chennai.  
Albumin Denaturation Assay Procedure 
In-vitro anti-inflammatory activity Vilva Oil (VO) was studied using albumin 
denaturation technique. The reaction mixture consisted of bovine serum albumin (5% 
aqueous solution) and test sample VO at varying concentration ranges from 100 to 500 
mcg/ml and standard diclofenac sodium at the concentration of100 mcg/ml of final 
volume. pH was adjusted by using a small amount of 1N Hydrochloric acid. The samples 
were incubated at 37°C for 20 min and then heated at 57°C for 3 min. After cooling the 
sample, 2.5 ml of phosphate buffer solution was added into each test tube. Turbidity 
developed was measured spectrophoto-metrically at 660 nm, for control distilled water 
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was used instead of test sample while product control tests lacked bovine serum albumin. 
The experiment was performed in triplicate. 
The Percentage protection from denaturation is calculated by using the formulae 
 
Statistical analysis: 
Results are expressed as Mean ± SD. The difference between experimental groups 
was compared by One-Way Analysis Of Variance (ANOVA) followed by Dunnet 
Multiple comparison test 
Preparation of Test and control 
 
Absorbance of reaction mixture – Test Sample 
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Absorbance of reaction mixture – Control and Standard 
 
4.2.2 Physicochemical Evaluation 
                 The Physicochemical analysis of the drug VILVA ENNAI was done at Noble 
Research Solutions, Sathyabama University, Chennai. Since the form of the drug is in oil 
the parameters such as Total ash, pH, Saponification value, Iodine value was done using 
Quality control methods for medicinal plants materials. 
Percentage Loss on Drying 
10gm of test drug (weight equivalent to oil) was accurately weighed in 
evaporating dish .The sample was dried at 105
o
C for 5 hours and then weighed. 
Percentage loss in drying = Loss of weight of sample/ Wt of the sample X 100 
Determination of Total Ash 
3 g  of test drug (weight equivalent to oil) was accurately weighed in silica dish 
and incinerated at the furnace a temperature 400 ºC until it turns white in color which 
indicates absence of carbon. Percentage of total ash will be calculated with reference to 
the weight of air-dried drug. 
Total Ash = Weight of Ash/Wt of the Crude drug taken X 100 
Determination of pH 
Sample being oily in nature the direct litmus evaluation method was adopted to 
check the pH of the sample.  
Determination of Iodine value  
About 20gm of oil was transferred into Iodine flask. To which 10 ml of 
chloroform was added and warmed slightly and cooled for 10 minutes. Followed by this 
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about 25 ml of Wiji‟s solution was added in the same flask and shaken well. The flask 
was allowed to stand for 30 min and refrigerated for an hour. About 10 ml of KI solution 
was added to this and titrated against 0.1 N Sodium thiosulphate solutions until the 
appearance of yellow colour. 1 ml of starch indicator was added and again titrated against 
the sodium thiosulphate solution from the burette. Disappearance of blue colour indicates 
end point. Repeat the above procedure without taking sample and note the corresponding 
reading for blank titration. 
Determination of saponification value  
About 2gm (weight equivalent to oil) of test sample was transferred into the round 
bottomed flask. To this about 20 ml of 0.5 N alcoholic KOH solutions was added to the 
round bottomed flask. Repeatthe same procedure without taking the sample for blank 
titration. Reflux both sample and blank round bottomed flasks for 1 hour. After reflux, 
allow both the round bottomed flasks to cool. Titrate the samples using 0.5 N HCl with 
phenolphthalein indicator. The disappearance of pink indicates the end point.  
GCMS- Analysis 
GCMS (Clarus 500 Perkin – elmer (Auto system XL)), NIST Ver.2.1 MS data 
library 
Specification : 
Start Time(min)   End Time(min)   Start m/z  End m/z Scan  Speed 
2.50   18.00   50.00   650.00   2000 
Sample Inlet Unit : GC 
 GC-MS Plays a key role in the analysis of unknown components of plant origin. 
GC-MS ionizes compound and measures their mass numbers. Ionization method includes 
EI (Electron Ionization). The EI method produces ions by colliding thermal electrons 
emitted from a filament with sample gas molecules. This method provides high stability 
in ionization and obtained mass spectra show good reproducibility. The EI method 
provides good result for quantitative analysis as well. Quantitative analysis with GC-MS, 
in which only ions specific to the compounds are measured, is highly selective method 
without interfering components. Gas chromatography Technique involves the separation 
of volatile components in a test sample using suitable capillary column coated with polar 
or non-polar or intermediate polar chemicals. Elite-1 column (100% Dimethyl 
65 
 
polysiloxane) is a non-polar column used for analysis of phyto-components. Elite -5 
column (5% phenyl and 95% methyl polysiloxane) is an intermediate column and also 
used for the estimation of Phytochemical. An inert gas such as hydrogen or nitrogen or 
helium is used as a carrier gas .The compounds of test sample is evaporated in the 
injection port of the GC equipment and segregated in the column by absorption and 
adsorption technique with suitable GC programme. 
TLC Analysis 
Test sample VO was subjected to thin layer chromatography (TLC) as per 
conventional one dimensional ascending method using silica gel 60F254, 7X6 cm 
(Merck) were cut with ordinary household scissors. Plate markings were made with soft 
pencil. Micro pipette were used to spot the sample for TLC applied sample volume 10-
micro liter by using pipette at distance of 1 cm at 5 tracks. In the twin trough chamber 
with different solvent system Ethyl acetate: Methanol: Water (100:13.5:10) After the run 
plates are dried and was observed using visible light Short-wave UV light 254nm and 
light long-wave UV light 365 nm. 
High Performance Thin Layer Chromatography Analysis (HPTLC) 
HPTLC method is a modern sophisticated and automated separation technique 
derived from TLC. Pre-coated HPTLC graded plates and auto sampler was used to 
achieve precision, sensitive, significant separation both qualitatively and quantitatively. 
High performance thin layer chromatography (HPTLC) is a valuable quality assessment 
tool for the evaluation of botanical materials efficiently and cost effectively. HPTLC 
method offers high degree of selectivity, sensitivity and rapidity combined with single-
step sample preparation. In addition it is a reliable method for the quantitation of nano 
grams level of samples. Thus this method can be conveniently adopted for routine quality 
control analysis. It provides chromatographic fingerprint of phytochemicals which is 
suitable for confirming the identity and purity of medicinal plant raw materials.  
Chromatogram Development 
It was carried out in CAMAG Twin Trough chambers. Sample elution was carried 
out according to the adsorption capability of the component to be analysed. After elution, 
plates were taken out of the chamber and dried. 
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Scanning 
Plates were scanned under UV at 366nm. The data obtained from scanning were 
brought into integration through CAMAG software. Chromatographic finger print was 
developed for the detection of phytoconstituents present in each extract and Rf values 
were tabulated.
 
Phytoconstituents of Vilva Ennai 
Sample Preparation 
Vilva oil (VO) was extracted with ethanol and the extract was subjected to the 
following analysis 
Test for Alkaloid- Mayer's reagent 
To the test drug about 2ml of Mayer's reagent was added and was observed for the 
presence of alkaloids. Appearance of dull white precipitate indicates the presence of 
alkaloids. 
Test for flavonoid 
To 0.1ml of the test sample about 5 ml of dilute ammonia solution were been 
added followed by addition of few drops of conc. Sulfuric acid. Appearance of yellow 
color indicates the presence of Flavonoids. 
Test for Glycosides - Borntrager‟s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a 
water bath, filtered and the hydrolysate is subjected to the following tests. To 2 ml of 
filtered hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer is 
separated and 10% ammomia solution is added to it. Pink colour indicates presence of 
glycosides. 
Test for Triterpenoids 
To the test solution 2ml chloroform was added with few drops of conc. Sulphuric 
acid (3ml) at the side of the test tube. An interface with a reddish brown coloration is 
formed if terpenoids constituent is present.  
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Test for Steroids - Salkowski test 
To the test solution 2ml of chloroform was added with few drops of conc. 
Sulphuric acid (3ml), and shaken well. The upper layer in the test tube was turns into red 
and sulphuric acid layer showed yellow with green fluorescence. It showed the presence 
of steroids. 
Test for Carbohydrates - Benedict‟s test 
To 0.5 ml of test drug about 0.5 ml of Benedic‟s reagent is added. The mixture is 
heated on a boiling water bath for 2 minutes. A characteristic coloured precipitate 
indicates the presence of sugar. 
Test – Phenol- Lead acetate test 
The test sample is dissolved in of distilled water and to this 3 ml of 10% lead 
acetate solution is added. A bulky white precipitate indicates the presence of phenolic 
compounds. 
Test for tannins  
About 0.5ml of test sample is boiled in 20 mL of distilled water in a test tube and 
then filtered. The filtration method used here is the normal method, which includes a 
conical flask and filter paper. The 0.1% FeCl3 is added to the filtered samples and 
observed for brownish green or a blue black coloration, which shows the presence of 
tannins 
Test for Saponins 
The test drugs were shaken with water vigorously for 10 mins , copious lather 
formation indicates the presence of saponins. 
Test for Proteins (Biuret Test) 
Biuret test: Equal volume of 5% solution of sodium hydroxide and 1% copper 
sulphate were added. Appearance of pink or purple colour indicates the presence of 
proteins and free amino acids. 
Test of Coumarins 
 1 ml of extract, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is indicated by the formation of yellow color. 
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Test for Anthocyanin 
About 0.2 ml of the extract was weighed in separate test tube, 1ml of 2N Sodium 
hydroxide was added, and heated for 5 minutes at 100 ± 2°C.  Observed for the formation 
of bluish green color which indicates the presence of anthocyanin. 
Quantitative estimation of phytoconstituents of Villva Ennai 
Determination of total Phenol content 
 The total phenol content was determined using Folin–Ciocalteu reagents with 
analytical grade Gallic acid as the standard. 1 ml of sample was added to deionized water 
(10 ml) and Folin–Ciocalteu phenol reagents (1ml). After 5 minutes, 20% sodium 
carbonate (2 ml) was added to the mixture. After being kept in total darkness for 1hr, the 
absorbance was measured at 750 nm using a spectrophotometer. Amounts of total Phenol 
was calculated using Gallic acid calibration curve. The results were expressed as Gallic 
acid equivalents (GAE) mg/g of dry plant matter. 
Estimation of Alkaloid 
 VO weight equivalent to 5gm was weighed into a 250 ml beaker and 200 ml of 
10% acetic acid in ethanol was added and covered and allowed to stand for 4 hr. This was 
filtered and the extract was concentrated on a water bath to one-quarter of the original 
volume. Concentrated ammonium hydroxide was added drop wise to the extract until the 
precipitation was complete. The whole solution was allowed to settle and the precipitated 
was collected and washed with dilute ammonium hydroxide and then filtered. The 
residue is the alkaloid, which was dried and weighed. 
4.2.3 Biocemical Analysis 
Biochemical Analysis of VILVA ENNAI was done at the Biochemistry lab at 
National Institute of Siddha, Chennai by the method of Kolkate. 
Preparation of Extract 
 5ml of sample was taken in a 250ml clean beaker and added with 50ml of 
distilled water. Then it is boiled well for about 10 minutes. Then it is cooled and filtered 
in a 100ml volumetric flask and made up to 100ml with distilled water. This preparation 
is used for the qualitative analysis of acidic/basic radicals and biochemical constituents in 
it. 
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Test for Silicate 
             A 2ml of the sample was shaken well with distilled water. 
Action of Heat 
           A 2ml of the sample was taken in a dry test tube and heated gently at first and then 
strong. 
Flame Test 
 2ml of the sample is made into a paste with con. Hcl in a watch glass and 
introduced into non- luminous part of the bunsan flame. 
Ash Test 
            A filter paper was soaked into a mixture of extract and dil. cobalt nitrate solution 
and introduced into the Bunsen flame and ignited 
4.2.3.1 Test for Acid Radicals 
Test for sulphate 
 2ml of the above prepared extract is taken in a test tube to this added 2ml of 4% 
ammonium oxalate solution. 
Test for Chloride 
 2ml of the above prepared extract is added with diluted Hno3 till the effervescence 
ceases. Then 2ml of silver nitrate solution is added. 
Test for Phosphate: 
 2ml of the extract is treated with 2ml of ammonium molybdate solution and 2ml 
of con.Hno3. 
 Test for Carbonate 
 2ml of the extract is treated with 2ml magnesium sulphate solution 
Test for Nitrate 
  1gm of substance is heated with copper turnings and concentrated H2So4 and 
viewed the test tube vertically down. 
  
70 
 
Test for Sulphide 
 1gm of the substance is treated with 2ml of con. HCL 
Test for Fluoride & Oxalate 
 2ml of extract is added with 2ml of dil. Acetic acid and 2ml calcium chloride 
solution and heated. 
Test for Nitrite 
 3drops of the extract is placed on a filter paper, on that – 2 drops of acetic acid 
and 2drops of Benzidine solution is placed. 
Test for Borate 
 2 Pinches of the substance is made into paste by using sulphuric acid and alcohol 
(95%) and introduced into the blue flame. 
4.2.3.2 Test for Basic Radicals 
Test for Lead 
 2ml of the extract is added with 2ml of potassium iodide solution. 
Test for copper 
 1 Pinch of substance is made into paste with con. HCL in a watch glass and 
introduced into the non-luminuous part of the flame  
Test for Aluminium 
 To the 2ml of the extract sodium hydroxide is added in drops to excess.  
Test for Iron 
 To the 2ml of extract add 2ml of ammonium thiocyanate solution. 
Test for Zinc 
 To 2ml of the extract sodium hydroxide solution is added in drops to exess. 
Test for Calcium 
 2ml of the extract is added with 2ml of 4% Ammonium oxalate solution. 
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Test for Magnesium 
  To 2ml of extract sodium hydroxide solution is added in drops to exess. 
Test for Ammonium 
 To 2ml of extract few ml of Nessler‟s reagent and exess of sodium hydroxide 
solution are added. 
Test for Pottasium 
 A pinches of the substance is treated with 2ml of sodium nitrite solution and then 
treated with 2ml of cobalt nitrate in 30% glacial acetic acid. 
Test for Sodium 
 3 pinches of the substance is made into paste by using HCL and introduced into 
the blue flame of Bunsen burner. 
Test for Mercury 
 2ml of extract is treated with 2ml of sodium hydroxide solution 
Test for Arcenic 
 2ml of the extract is treated with 2ml of sodium hydroxide solution.     
4.2.3.3 Miscellaneous 
Test for Starch 
 2ml of extract is treated with weak iodine solution. 
Test for Reducing Sugar 
 5ml of Benedict‟s qualitative solution is taken in a test tube and allowed to boil 
for 2 minutes and added 8 to 10 drops of the extract and again boil it for 2 minutes. The 
colour changes are noted.  
Test for the Alkaloids 
 2ml of the extract is treated with 2ml of potassium iodide solution. 
Test of Tannic acid 
 2ml of extract is treated with 2ml of ferric chloride solution. 
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Test for Unsaturated Compound 
 To the 2ml of extract 2ml of potassium permanganate solution is added. 
Test for Amino Acid 
 2 drops of the extract is placed on a filter paper and dried well. 
Test for Type of Compound 
 2ml of the extract is treated with 2ml of ferric chloride solution.   
4.3 CLINICAL STUDIES 
                   A Protocol was prepared and submitted before IEC of National Institute of siddha. 
The IEC approval number is NIS/IEC/9/2014-15/17, and my registered CTRI number is 
CTRI/2017/02/007753. After getting the approval from committee, the clinical study on Vali 
Kanam (Acute Pharyngitis) in children and the drug of choice was Vilva Ennai carried out as 
per the protocol. 
The trial drug “VIVA ENNAI” is given for 5 days. For OP patients before and 
after treatment the clinical assessment will be done and prognosis is noted. For IP 
patients the drug is provided daily and prognosis is noted and clinical assessment will be 
done. After the end of the treatment, the patient were advised to visit the OPD for follow 
up regularly.    
Study Enrollment 
1. In this study, patients reporting at the NIS OPD with the three or  more clinical 
symptoms of rumbling noise in stomach, irritant sensation in throat, cough, excessive 
thirst, low-grade fever, lack  of appetite, dysuria will be examined clinically for enrolling 
in this study based on the inclusion and exclusion criteria. 
2. The patients who are to be enrolled would be informed about the study, 
experimental medicine, possible outcomes and the objectives of the study in the language 
and terms understandable to them and to their informants. 
3. After ascertaining the patient and informants willingness, informed consent 
would be obtained in writing from them in the consent form. 
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   4. Complete clinical history, complaints and duration, examination findings-- all 
would   be recorded in the prescribed Performa in the history and clinical assessment 
forms separately. Screening Form- I will be filled up. Form –IV will be used for 
recording the patients‟ history, clinical examination of symptoms and signs and 
laboratory investigations respectively. 
          5. Patients would be advised to take the trial drug and appropriate dietary advice 
would be given according to the patients‟ perfect understanding. 
Population and Sample 
 The population consists of paediatric patients attending the OPD of Ayothidoss 
Pandithar Hospital, National Institute Of Siddha, Chennai-47. 
 The sample consists of 8-12 years age group fulfilling all the inclusion criteria 
and none of the exclusion criteria. 
Study type:  An Open Clinical Trial 
Sample size: 40 patients (Both male & female)          
Study place: 
  Department of Kuzhanthai Maruthuvam 
                       OPD & IPD of Ayothidoss pandithar hospital, 
                       National Institute of Siddha,  
                       Chennai – 47                               
Inclusion Criteria 
 Age 8-12 years 
 Both sex ( male &female children) 
 Patients with symptoms of 
 cough,  
 Low grade fever, 
 Sore throat. 
 loss of  appetite, 
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 Willing to attend the OPD.   
 Willing to give biological sample if necessary    
Exclusion Criteria 
 H/O Active primary complex 
 Tonsillitis 
 Congenital heart disease 
 Severe asthma 
 Long term fever 
 Any other serious illness 
 Withdrawl Criteria 
 Occurrence of any drug adverse effect such as diarrhea, nausea, vomiting, 
abdominal pain, indigestion. 
 Poor patient compliance &defaulters.  
 Patient turned unwilling to continue in the course of clinical trial drug.  
 Exacerbation of symptoms. 
 Study duration: 24 Months 
 Dose:  3 ml (OD – morning) 
       Dose calculation for paediatric group is based on Age, Formula mentioned in the 
Gunapadam Thathu Jeeva Vaguppu text.  
ASSESSMENT 
 Clinical assessment  
 Routine Investigation 
 Siddha method of assessment 
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Clinical Assessment  
 Sore throat scale 
 G0 -normal 
 G1 -Mild discomfort 
 G2 -Hoarsness of voice only. 
 G3 -Hoarsness of voice associated with Throat pain while speaking. 
 G4 -Hoarsness of voice associated with throat pain and difficult to 
swallowing                                                        
 G5 -Severe throat pain with all above symptoms. 
 Cough Assessment 
(Each item carries two points and the total score will be assessed from the 
following       
 Had chest pain or stomach pain during cough             
 Sputum production while coughing                     
 Sleep disturbances due to cough  
 Cough interrupting conversation  
 Cough present at rest  
 Appetite scale 
 G0 -Normal   
 G1 -Mild appetite but eating time being 
 G2 -Interest only to take junk foods 
 G3 -No interest to take any type of food but on compulsion he/she takes                                                                                              
foods. 
 G4 -doesn‟t take food even on compulsion. 
 Temperature scale 
 G0 -Normal 
 G1 –Low grade fever    
Investigation 
                       TC, DC, ESR 
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Siddha Method of Assessment 
 Nilam  
 Kaalam 
 Uyir Thathukkal 
 Udal Thathukkal 
 Envagai Thervugal 
OUTCOME 
Primary outcome 
 Reduction in the cough is assessed by modified LCQ (Leicester Cough 
Questionnaire). 
 Reduction in the temperature is assessed by clinical thermometer. 
 Reduction in sore throat and associated symptoms. 
 Secondary outcome: 
 Clinical efficacy of the trial drug and side effects if any… 
 The experimental drug may have good efficacy and safety in clinical study. 
 Data Management 
 After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Whenever study patient visits 
OPD during the study period, the respective patient file will be taken and 
necessary recordings will be made at the assessment form or other suitable 
form. 
  The screening forms will be filed separately. 
 The Data recordings will be monitored for completion and adverse event by 
HOD and data logical recording and completeness will be monitored by 
statistician (Sr.Research Officer (Statistics)). All forms will be further 
scrutinized in presence of Investigators by Sr.Research Officer (Statistics) for 
logical errors and incompleteness of data before entering onto computer to 
avoid any bias. No modification in the results is permitted for unbiased 
report. 
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 Any missed data found in during the study, it will be collected from the 
patient, but the time related data will not be recorded retrospectively 
 All collected data will be entered using MS access software onto computer. 
 Investigators will be trained to enter the patient data and cross checked by 
SRO 
Adverse Effect/Serious Effect Management 
 If the trial patient develops any adverse reaction such as diahrroea, vomiting, 
nausea, abdominal pain, indigestion he/she would be immediately withdrawn from the 
trial and proper management will be given in OPD of National institute of siddha and the 
same will be reported to regional pharmacovigilance center. 
Ethical Issues 
1. To prevent any infection, with proper sterilization of lab equipments will be used.                         
2. No other external or internal medicines will be used. 
3. The data collected from the patient‟s informant will be recorded. The patient‟s 
informant will be informed about the diagnosis, treatment and follow-up.  
4. After the consent of the patient‟s informant (through consent form), patient will 
be enrolled in the study.  
5. Informed consent will be obtained from the patient‟s informant explaining in the 
understandable language to the patient‟s informant. 
6. Treatment would be provided free of cost. 
7. In conditions of treatment failure, adverse reactions, patients will be given 
alternative treatment at the National Institute of Siddha with full care. 
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DATA COLLECTION FORMS 
Form I          Screening & Selection Performa 
Form II        Consent Form 
Form II A     Assent Form 
Form III       Case Report Form 
Form IV       Patient Information sheet 
Form V        Diet form 
Form VI       Drug compliance 
Form VII      Adverse Effect Form 
Form VIII     Withdrawl Form 
Form IX        Pharmacovigilance 
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5. RESULTS AND OBSERVATIONS 
5.1 PRECLINICAL STUDIES 
5.1.1 In-vitro Anti-Inflammatory Activity 
Protein (Albumin) denaturation Assay 
Table: 1. Influence of trial drug against Protein Denaturation.  
Concentration in µg/ml 
Percentage Inhibition of Protein 
Denaturation 
VO 100 29.32  ± 9.92 
VO 200 37.31  ± 10.24 
VO 300 46.76  ± 10.99 
VO 400 61.43  ± 5.64 
VO 500 72.12  ± 5.08 
Diclofenac sodium (100 µg) 86.16  ± 5.07 
Table: 2. Absorbance of Reaction micture  
 Concentration in µg/ml Absorbance 
Control 0.87  ± 0.05 
VO 100 0.51  ± 0.026 
VO 200 0.44  ± 0.036 
VO 300 0.35  ± 0.032 
VO 400 0.23  ± 0.017 
VO 500 0.13  ± 0.025 
Diclofenac sodium  (100 µg) 0.013  ± 0.005 
Each value represents the mean ± SD. N=3 
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Result Analysis 
The result obtained from the present clearly indicates that the test drug VO was 
effective in inhibiting heat induced albumin denaturation. Maximum percentage 
inhibition of about 72.12 % was observed at 500 μg/ml when compare to that of the 
Diclofenac sodium, a standard anti-inflammatory agent with the maximum inhibition 
86.16 % at the concentration of 100 μg/ml. 
Conclusion 
From the result of the study it was concluded that the test drug VO possess 
promising anti-inflammatory property in protein denaturation assay. 
Absorbance Range of test and standard at Trial 1 
   
Absorbance Range of test and standard at Trial 2 
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Absorbance Range of test and standard at Trial 3  
  
5.1.2 Physicochemical evaluation of Vilva Ennai (Table: 3 & 4) 
Parameter Observation 
Color Dark Greenish black  
Smell Characteristic odour 
Touch Oily 
Appearance Dense 
 
S.No Parameter Mean (n=3) SD 
1 Loss on Drying at 105 °C (%) 0.9 ± 0.43 
2 Total Ash (%)  0.588 ± 0.11 
 
  
82 
 
Inference 
 In Vilva Ennai, the loss on drying at 105
o
C was found to be 0.9%. Low moisture 
content shows the good stability of the drug. 
 The total ash in Vilva Ennai found to be 0.58%. The minimal level of total ash 
shows the purity of the drug.    
Table: 5 Physicochemical evaluation of Vilva Ennai. 
S.No Specific Test VO 
1 pH  6 
2 Refractive index  1.46 
3 Iodoine value (mg I2/g) 102 
4 Saponification Value  (mg of KOH to saponify 1gm of fat) 211 
 
GC-MS Chromatogram of Vilva Ennai 
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Table: 6. Peak Report of Vilva Ennai 
Peak# R.Time Area Area% Height Height% 
1 4.115 590645 1.43 196400 0.87 
2 4.288 167128 0.40 95797 0.43 
3 5.429 249089 0.60 188313 0.84 
4 5.493 102147 0.25 78344 0.35 
5 5.590 324384 0.78 199007 0.89 
6 5.692 195138 0.47 142302 0.63 
7 5.762 216306 0.52 123297 0.55 
8 5.844 257244 0.62 213747 0.95 
9 5.910 404391 0.98 330633 1.47 
10 6.138 497363 1.20 405334 1.81 
11 6.187 83831 0.23 74439 0.33 
12 7.064 468697 1.13 253101 1.13 
13 7.139 260117 0.63 214755 0.96 
14 7.302 224848 0.54 143098 0.64 
15 7.411 447202 1.08 375811 1.67 
16 7.474 994172 2.40 539934 2.39 
17 7.731 3176822 7.68 2799722 12.47 
18 7.821 7888389 19.07 4466597 19.89 
19 7.911 1726460 4.17 1463642 6.52 
20 7.947 1612300 3.90 1353469 6.03 
21 8.025 3566936 8.62 2972562 13.24 
22 8.208 335051 0.81 294266 1.31 
23 8.383 231928 0.56 198576 0.88 
24 8.750 1318912 3.19 744576 3.32 
25 9.026 715722 1.73 348025 1.55 
26 10.959 2957143 7.15 1179320 5.25 
27 13.098 4051123 9.79 1227482 5.47 
28 13.188 6218773 15.03 1267411 5.64 
29 14.007 2085784 5.04 565872 2.52 
    41368045 100.00 22455832 100.00 
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TLC Analysis:  
Visible         Short UV  Long UV        TLC Chromatogram       
                                             
High Performance Thin Layer Chromatogram of Vilva Ennai 
 
Table:7. Peak Table of HPTLC finger printing of Vilva Ennai 
Peak 
Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area 
Area 
% 
1 0.34 1.1 0.35 16.5 21.67 0.39 5.8 260.9 11.26 
2 0.54 9.4 0.61 59.6 78.33 0.67 2.6 2056.3 88.74 
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Table: 8. Qualitative estimation of Phytoconstituents of Vilva Ennai 
PHYTOCOMPONENTS VILVA ENNAI 
ALKALOIDS + 
FLAVONOIDS - 
GLYCOSIDES - 
STEROIDS + 
SUGAR + 
TRITERPNOIDS - 
COUMARINS - 
PHENOLS + 
TANNINS - 
SAPONINS + 
PROTEINS + 
ANTHOCYANIN - 
 
+   Indicates positive 
- Indicates Negative 
 
Table: 9. Quantitative estimation of phytoconstituents of Vilva Ennai 
Phyto- constituents Vilva Ennai 
Total phenols (GAE mg/gm) 0.67 ± 0.18 
Total alkaloids(mg/gm) 1.56 0.31 
Mean with 3 replicates ± SD. 
Inference: 
 In Vilva Ennai, the presence of Phytoconstituents such as Alkaloid, Steroid, 
Sugar, Phenols, Saponin and protein are present. 
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Test for Alkaloid- Mayer's reagent     Test for Glycosides - Borntrager‟s Test 
      
  
    
 
      
            Test for flavonoid                                    Test for Triterpnoids 
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Test for Steroids Salkowski test Test for Carbohydrates  Benedict‟s test 
                                                                         
                                                     
           
   
   Test for Anthocyanin                                         Test of Coumarins   
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.    
 Test – Phenol- Lead acetate test                      Test for tannins  
  
                                                                      
 
  
  
    Test for Saponins                                 Test for Proteins (Biuret Test) 
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5.1.3 Test for Heavy Metals 
Method of Testing 
 BVCPSCH/INS/SOP/053 by ICP OES  
Table: 10 Result of heavy metals in trial drug.  
S.No Test Parameters 
Units of 
Measurement 
Result 
1 Cadmium mg/kg ND (DL - 0.01) 
2 Lead mg/kg ND (DL - 0.01) 
3 Mercury mg/kg ND (DL - 0.01) 
4 Arsenic mg/kg ND (DL - 0.01) 
Inference 
 The heavy metals such as Cadmium, Lead, Mercury, Arsenic are not detected in 
my trail drug Vilva Ennai. 
5.1.4 Test for Aflatoxin 
Method of Testing 
 AOAC2008.02 
Table: 11. Result of Aflatoxin in trial drug  
S.No Test Parameters 
Units of 
Measurement 
Result 
1 Aflatoxin B1 µg/kg BLQ (LOQ: 0.5) 
2 Aflatoxin B2 µg/kg BLQ (LOQ: 0.5) 
3 Aflatoxin G1 µg/kg BLQ (LOQ: 0.5) 
4 Aflatoxin G2 µg/kg BLQ (LOQ: 0.5) 
Inference 
 The level of Aflatoxin is below the limit of quantification. So the drug Vilva 
ennai shows the absence of aflatoxin. 
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5.1.5 Test for Pesticide 
Test for Organochlorine 
Method of Testing 
 EURL Method by GC MSMS/ LC MSMS 
Table: 12. Result of Organochlorine in trial drug 
S.No Test Parameters 
Units of 
Measurement 
Result 
1 
Aldrin(Aldrin and dieldrin combined 
expressed as dieldrin) 
mg/kg BLQ (LOQ: 0.01) 
2 Chlordane(cis & trans) mg/kg BLQ (LOQ: 0.01) 
3 Chlorothalonil mg/kg BLQ (LOQ: 0.01) 
4 DDT (all Isomers) mg/kg BLQ (LOQ: 0.01) 
5 Dicofol (sum of p,p'  and o,p' Isomers) mg/kg BLQ (LOQ: 0.01) 
6 Dieldrin (see Aldrin) mg/kg BLQ (LOQ: 0.01) 
7 Endosulphan(all Isomers) mg/kg BLQ (LOQ: 0.01) 
8 Endrin mg/kg BLQ (LOQ: 0.01) 
9 
HCH (sum of isomers, except the 
gamma isomers) 
mg/kg BLQ (LOQ: 0.01) 
10 
Heptachlor (sum of heptachlor and 
heptachlorepoxide expressed as 
heptachlor) 
mg/kg BLQ (LOQ: 0.01) 
11 Lindane(gamma-HCH) mg/kg BLQ (LOQ: 0.01) 
Test for Organophosphosphorus 
Method of Testing 
 EURL Method by GC MSMS/ LC MSMS 
Table: 13. Result of Organophosphorus in trial drug 
S.No Test Parameters Units of 
Measurement 
Result 
12 4-bromo-2-chlorophenol (metabolite 
of Profenophos) 
mg/kg BLQ (LOQ - 0.01) 
13 Acephate mg/kg BLQ (LOQ - 0.01) 
14 Chlorfenvinphos mg/kg BLQ (LOQ - 0.01) 
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15 Chlorpyrifos mg/kg BLQ (LOQ - 0.01) 
16 Chlorpyrifosmethyl mg/kg BLQ (LOQ - 0.01) 
17 Diazinon mg/kg BLQ (LOQ - 0.01) 
18 Dichlorvos mg/kg BLQ (LOQ - 0.01) 
19 Dimethoate(including Omethoate) mg/kg BLQ (LOQ - 0.01) 
20 Edifenphos mg/kg BLQ (LOQ - 0.01) 
21 Ethion mg/kg BLQ (LOQ - 0.01) 
22 Etrimphos mg/kg BLQ (LOQ - 0.01) 
23 Fenitrothion mg/kg BLQ (LOQ - 0.01) 
24 Fenthion mg/kg BLQ (LOQ - 0.01) 
25 Iprobenphos mg/kg BLQ (LOQ - 0.01) 
26 Malathion (sum of malathion and 
malaoxon expressed as malathion) 
mg/kg BLQ (LOQ - 0.01) 
27 Methamidophos mg/kg BLQ (LOQ - 0.01) 
28 Monocrotophos mg/kg BLQ (LOQ - 0.01) 
29 Omethoate (refer to Dimethode)  mg/kg BLQ (LOQ - 0.01) 
30 Oxydemeton-methyl (sum of 
parathion methyl and demeton-S-
methyl sulfone expressed as 
oxydemeton methyl) 
mg/kg BLQ (LOQ - 0.01) 
31 P t i  ethyl mg/kg BLQ (LOQ - 0.01) 
32 Parathion Methyl (sum of parathion 
methyl paraoxon methyl expressed 
as parathion methyl) 
mg/kg BLQ (LOQ - 0.01) 
33 Phenthoate mg/kg BLQ (LOQ - 0.01) 
34 Phorate (sum of phorate, its oxygen 
analogue and their sulfones 
expressed as phorate) 
mg/kg BLQ (LOQ - 0.01) 
35 Phosalone mg/kg BLQ (LOQ - 0.01) 
36 Phosphamidon mg/kg BLQ (LOQ - 0.01) 
37 Pirimiphos methyl mg/kg BLQ (LOQ - 0.01) 
38 Profenophos mg/kg BLQ (LOQ - 0.01) 
39 Propetamphos mg/kg BLQ (LOQ - 0.01) 
40 Ouinalphos mg/kg BLQ (LOQ - 0.01) 
41 Temephos mg/kg BLQ (LOQ - 0.01) 
42 Thiometon mg/kg BLQ (LOQ - 0.01) 
43 Triazophos mg/kg BLQ (LOQ - 0.01) 
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Test for Synthetic Pyrethroids 
Method of Testing 
 EURL Method by GC MSMS/ LC MSMS 
Table: 14. Result of Synthetic pyrethroids in trial drug 
S.No Test Parameters 
Units of 
Measurement 
Result 
44 Allethrin and Bioallerthin mg/kg BLQ (LOQ: 0.01) 
45 Bifenthrin mg/kg BLQ (LOQ: 0.01) 
46 
Cypermethrin(including other 
mixture of constituent isomers sum 
of isomers) 
mg/kg BLQ (LOQ: 0.01) 
47 Deltamethrin mg/kg BLQ (LOQ: 0.01) 
48 Ethofenprox(Etofenprox) mg/kg BLQ (LOQ: 0.01) 
49 Fenpropathrin mg/kg BLQ (LOQ: 0.01) 
50 
Fenvalerate(sum of RR & SS 
isomers) 
mg/kg BLQ (LOQ: 0.01) 
51 Lambda-cyhalothrin mg/kg BLQ (LOQ: 0.01) 
52 Permethrin (sum of isomers) mg/kg BLQ (LOQ: 0.01) 
53 tau-Fluvalinate mg/kg BLQ (LOQ: 0.01) 
54 Transfluthrin mg/kg BLQ (LOQ: 0.01) 
 
Inference 
This study reveals the absence of pesticides, Organophosphorus, Organochlorine 
and synthetic pyrethroids in the trail drug Vilva Ennai. 
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5.1.6 Test for Microbiological 
Method of Testing  
 API Volume-II 
Table: 15. Result of Micro-organism in trial drug 
S.No Test Parameters 
Units of 
Measurement 
Result 
1 E.coli Per g Absent 
2 Pseudomonas aeruginosa Per g Absent 
3 Salmonella Per g Absent 
4 Staphylococcus aureus Per g Absent 
Inference 
 The Microbiological test reveals the absence of micro-organism such as E.coli, 
Pseudomonas aeruginosa, Salmonella and Staphylococcus aureus in the trial drug Vilva 
Ennai. 
5.1.7 Biochemical analysis 
Results of Acid radicals studies (Table:16) 
S.No Parameter Observation Result 
1 Test for Sulphate - Negative 
2 Test for Chloride Cloudy appearance present Positive 
3 Test For Phosphate - Negative 
4 Test For Carbonate - Negative 
5 Test For Nitrate - Negative 
6 Test for Sulphide - Negative 
7 
Test For Fluoride & 
oxalate 
Cloudy appearance present Positive 
8 Test For Nitrite - Negative 
9 Test For Borax - Negative 
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Interpretation 
 The acidic radicals test shows the presence of Chloride, Fluoride & Oxalate. 
Table: 17. Results of basic radicals studies 
S.NO Parameter Observation Result 
1 Test for Lead - Negative 
2 Test for Copper - Negative 
3 Test For Aluminium. - Negative 
4 Test For Iron. - Negative 
5 Test For Zinc - Negative 
6 Test for Calcium - Negative 
7 Test For Magnesium - Negative 
8 Test For Ammonium Mild brown color appears Positive 
9 Test For Potassium - Negative 
10 Test For Sodium - Negative 
11 Test For Mercury - Negative 
12 Test For Arsenic - Negative 
Interpretation  
 The basic radical test shows the presence of Ammonium, and absence of heavy 
metals such as lead, Iron, arsenic and mercury. 
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Table: 18.  Results of Miscellaneous 
S. No Parameter Observation Result 
1 Test for Starch - Negative 
2 Test for Reducing sugars - Negative 
3 Test For Alkaloids. - Negative 
4 Test For Tannic acid - Negative 
5 
Test for unsaturated 
compounds 
- Negative 
6 
Test for Type of 
compounds 
- Negative 
Interpretation 
The Miscellaneous test shows the absence of Alkaloids, Tannic acid, Type of 
compounds. 
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5.2 CLINICAL STUDIES 
40 patients with confirmed diagnosis of VALI KANAM with satisfying inclusion 
criteria were enrolled after obtaining written informed consent and were received VILVA 
ENNAI with dosage of 3ml OD for 5 days. 
Results were observed with respect to the following criteria: 
1. Age 
2. Sex 
3. Patient‟s Socio Economic Status 
4. Religion 
5. Diet 
6. Nilam 
7. Paruvakaalam 
8. Uyir thathukkal 
9. Udal thathukkal 
10. Envagaithervugal 
11. Neikuri 
12. Clinical features 
13. Biochemical Analysis 
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Table: 19.  Distributions of Children with Vali Kanam according to Age 
 
 
 
Inference: 
 Out of 40 patients, 60% of cases were 8-10 years, 40% of cases were 11-12 years. 
The highest incidence was seen in the age group of 8-10 years. School going age group is 
most affected. 
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S.No Age No. of cases Percentage 
1 8-10 years 24 60% 
2 11-12 years 16 40% 
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Table:20. Distributions of Children with Vali Kanam according to Gender 
S. No Sex No. of cases Percentage 
1 Male Child 19 47.5% 
2 Female Child 21 52.5% 
 
 
Inference: 
Out of 40 patients 47.5% were male children and 52.5% were female children. 
According to this study both sexes were more or less equally affected which shows Vali 
Kanam is not predominant on sex.  
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Table: 21.  Distribution of Children with Vali Kanam according to socio-economic 
status 
S.No Socio Economic Status No. of cases Percentage 
1 Upper Class 3 7.5% 
2 Upper Middle 11 27.5% 
3 Lower Middle 24 60% 
4 Lower 2 5% 
 
 
Inference:  
About 7.5% patients were under upper class, 27.5% patients were under upper 
middle class, 60% patients were under Lower middle class and 5% patients were lower 
class. The highest incidence occurred in lower middle income group due to overcrowding 
and poor sanitation. 
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Table:22. Distribution of Children with Vali Kanam according to religion 
S.No Religion No. of cases Percentage 
1 Hindu 36 90% 
2 Muslim 1 2.5% 
3 Christian 3 7.5% 
 
 
Inference:  
About 90% patients were Hindu, 7.5% patients were Christian, 2.5% patients 
were Muslim. 
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Table:23. Distribution of Children with Vali Kanam according to Diet reference 
S.No Food Habits No. of cases Percentage 
1 Vegetarian 2 5% 
2 Non Vegetarian 38 95% 
 
 
Inference:  
 According to diet, Vegetarian 5%, Non vegetarian 95% were noted. The highest 
incidence was seen in Non-Vegetarian. But Vali Kanam has no influence on diet. 
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Table:24. Distribution of Children with Vali kanam according to Nilam 
S.No Nilam No. of cases Percentage 
1 Kurinji 2 5% 
2 Marutham 6 15% 
3 Neithal 32 80% 
4 Palai 0 0% 
5 Mullai 0 0% 
 
 
Inference: 
Among 40 patients, 80% were from Neithal land, 15 % from Marutham land, 0 % 
from Mullai land, and 5% from Kurinji land. Since this study was carried out in Chennai. 
The highest incidence of people seaking  treatment were from the sourrounding of 
Chennai, highest incidence was noted in Neithal nilam.  
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Table:25 Distribution of Children with Vali Kanam according to Paruvakaalam 
S.No Paruvakaalam No. of cases Percentage 
1 Ilavenil (Chitirai, Vaigasi) 0 0% 
2 Mudhuvenil (Aani, Aadi) 0 0% 
3 Kar kaalam(Avani – puratasi) 0 0% 
4 Koothir kaalam (Iyppasi –karthikai) 1 2.5% 
5 
Munpani kaalam(Markazhi uvak– 
Thai) 
21 52.5% 
6 Pinpani kaalam (Masi – Panguni) 18 45% 
 
 
Inference:  
Among 40 patients, 52.5 % were from Munpani kaalam, 45 % from Pinpani 
kaalam, 2.5%  from Koothir kaalam. The highest incidence was noted in munpanikaalam. 
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Table:26. Distribution of Children with Vali Kanam according to derangement of 
Vatham 
S.No Vatham No. of cases Percentage 
1 Pranan 40 100% 
2 Abanan 7 17.5% 
3 Viyanan 0 0% 
4 Uthanan 30 75% 
5 Samanan 40 100% 
6 Nagan 0 0% 
7 Koorman 0 0% 
8 Kirukaran 40 100% 
9 Devathathan 0 0% 
10 Thananjeyan 0 0% 
 
 
Inference:  
           According to vatham, derangement of Pranan was 100% due to poor appetite, 
Abanan was 17.5% due to constipation, Uthanan was 75% due to sore throat and 
difficulty in swallowing, samaanan was affected 100% due to vatham and Kirukaran was 
deranged in 100%. 
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Table:27. Distribution of Children with Vali Kanam according to derangement of 
Pitham 
S.No Pitham No. of cases Percentage 
1 Analagam 40 100% 
2 Ranjagam 6 15% 
3 Sathagam 0 0% 
4 Prasagam 0 0% 
5 Aalosagam 0 0% 
 
 
Inference:  
According to Pitham, derangement of Analapitham was 100% due to poor 
appetite and Ranjagapitham was deranged in 15% due to pallor of tongue and conjuctiva. 
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Table:28. Distribution of Children with Vali Kanam according to dearrangement of 
Kabam 
S.No Kabam No. of cases Percentage 
1 Avalambagam 40 100% 
2 Kilethagam 40 100% 
3 Podhagam 0 0% 
4 Tharpagam 0 0% 
5 Santhigam 0 0% 
 
 
Inference:  
 According to Kabam, derangement of Kelathagam was 100 % due to poor 
appetite and Avalambagam was deranged in 100%. 
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Table:29. Distribution of Children with Vali Kanam according to derangement of  
Ezhu Udalthadhukkal 
S.No Udalthadhu No. of cases Percentage 
1 Saaram 40 100% 
2 Senneer 6 15% 
3 Oon 0 0% 
4 Kozhuppu 0 0% 
5 Enbu 0 0% 
6 Moolai 0 0% 
7 Sukkilam 0 0% 
 
 
Inference:  
According to the study, Saram was affected in 100% of cases due to presence of 
fatigue, Senneer was affected in 15% due to pallor of tongue and conjunctiva. 
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Table:30. Distribution of Children with vali kanam according to derangement of  
Enn vagai  Thervugal 
S.No Envagai Thervugal No. of cases Percentage 
1 Naa 4 10% 
2 Niram 0 0% 
3 Mozhi 14 35% 
4 Vizhi 4 10% 
5 Malam 8 20% 
6 Moothiram 0 0% 
7 Naadi 0 0% 
8 Sparisam 7 17.5% 
 
 
Inference: 
               Out of 40 cases, 35% of the cases were affected by Mozhi. Malam was affected 
in 20% of patients due to constipation, 17.5% of cases affected by sparisam due to fever, 
10% 0f cases affected by naa and 10% of the cases affected by vizhi due to pallor of the 
tongue and conjunctiva. In Naadi, Vathapitham was observed in 50 % of cases, 
Pithavatham was observed in 40 % of cases, Pithakabam was observed in 10 % of cases.  
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Table:31. Distribution of Children with Vali Kanam according to observation of  
Neikuri analysis 
S.No Neikuri No. of cases Percentage 
1 Vatham 11 27.5% 
2 Pitham 12 30% 
3 Kabam 17 42.5% 
 
 
Inference 
 According to Neikuri, Vatha neer was observed in 27.5 % of cases, pitha neer 
was observed in 30% of cases, Kaba neer was observed in 42.5 % of cases. 
 
 
 
  
0
5
10
15
20
25
30
35
40
45
Vatham Pitham Kabam
11 12 
17 
27.5% 
30% 
42.5% 
Neikuri 
No. of cases
Percentage
110 
 
5.2.1 Clinical assessment 
 Cough Scale 
(Each item carries two points and the total score will be assessed from the 
following)         
1. Had chest pain or stomach pain during cough             
2. Sputum production while coughing                     
3. Sleep disturbances due to cough  
4. Cough interrupting conversation  
5. Cough present at rest  
Table:32. Distribution of children with Cough scale 
S.NO Score 
Before 
Treatment 
Percentage 
After 
Treatment 
Percentage 
1 10 5 12.5 0 0 
2 8 6 15 0 0 
3 6 17 42.5 1 2.5 
4 4 12 30 5 12.5 
5 2 0 0 15 37.5 
6 0 0 0 19 47.5 
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Infernce: 
Among the 40 cases, 12.5% of the patients were noted to have score of 10, 15% 
of the patients were noted to have score of 8, 42.5% of the patients were noted to have the 
score of 6, 30% were noted to have score of 4, at the base of treatment.  At the end of the 
treatment 0% of the patients were noted to have score of 10 & 8, 2.5% of the patients 
were noted to have score of 6, 12.5% of the patients were noted to have score of 4, 37.5% 
of the patients were noted to have the score of 2, 47.5% of the patients were noted to have 
score of 0. 
 Sore Throat Scale 
 G0 -Normal 
 G1 -Mild discomfort 
 G2 - Hoarseness of voice only. 
 G3 - Hoarseness of voice associated with Throat pain while speaking. 
 G4 -Hoarseness of voice associated with throat pain and difficult to 
swallowing                                                        
 G5 -Severe throat pain with all above symptoms 
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Table:33. Distribution of children with Sore Throat Scale 
S.NO Grade 
Before 
Treatment 
Percentage After Treatment Percentage 
1 G0 0 0 23 57.5 
2 G1 0 0 10 25 
3 G2 0 0 3 7.5 
4 G3 2 5 1 2.5 
5 G4 23 57.5 3 7.5 
6 G5 15 37.5 0 0 
 
 
Inference: 
 Among the 40 cases, 15 % of the patients were noted in G5, 23% of patients were 
noted   in G4, 2% were noted in G3 at the base of treatment.  At the end of the treatment 
57.5% of the cases were noted in G0, 25% of the patients were noted in G1, 7.5% of the 
patients were noted in G2&G4, 2.5% of the patients were noted in G3. 
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 Temperature scale 
 G0 -Normal 
 G1 –Low grade fever   
Table:34. Distribution of patients with Temperature scale 
S.NO Grade 
Before  
Treatment 
Percentage 
After 
Treatment 
Percentage 
1 G0 17 42.5 40 100 
2 G1 23 57.5 0 0 
 
 
Inference: 
             Among the 40 cases, after completion of treatment, 0 % of the patients were 
noted in G1, 100% of patients were noted   in G0. 
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 Appetite scale 
 G0 -Normal   
 G1 -Mild appetite but eating time being 
 G2 -Interest only to take junk foods 
 G3 -No interest to take any type of food but on compulsion he/she takes                                                                                               
foods. 
 G4 -doesn‟t take food even on compulsion. 
Table:35. Distribution of children with Appetite scale 
S.NO Grade Before  Treatment Percentage After Treatment Percentage 
1 G0 0 0 35 87.5 
2 G1 0 0 4 10 
3 G2 16 40 0 0 
4 G3 20 50 1 2.5 
5 G4 4 10 0 0 
6 G5 0 0 0 0 
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Inference:   
Among the 40 cases, 42.5 % of the patients were noted in G4, 32.5 % were noted   in 
G3,5 % were noted in G2, at the base of treatment. At the end of the treatment 10% of the 
cases were noted in G3, 22.5% of the cases were noted in G1, 7.5 % of the cases were 
noted in G0. 
Distribution of Children with Vali Kanam according to treatment results obtained 
Table:36. Cough  
S.No 
Before Treatment After Treatment 
Total 
Number of 
Cases Score 0 2 4 6 
1 Mild (4) 6 6 0 0 12 
2 Moderate (6) 4 9 3 1 17 
3 
Moderate Severe 
(8) 
4 0 2 0 6 
4 Severe (10) 5 0 0 0 5 
5 Total 19 15 5 1 40 
 
According to this study, 40 children came with the complaints of mild, moderate 
and severe cough. After the treatment, out of 40 children 19 (47.5%) has completely 
cured.  
Table:37. Sore throat 
S.No 
Before 
Treatment 
After Treatment 
Total 
Number 
of Cases Grade G0 G1 G2 G3 G4 
1 G3 2 0 0 0 0 2 
2 G4 14 6 0 1 2 23 
3 G5 7 4 3 0 1 15 
4 Total 23 10 3 1 3 40 
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 According to this study, 40 children came with the complaints of G3, G4, G5. 
After the treatment, out of 40 children 23 (57.5%)  has completely cured. 
Table:38. Appetite 
S.No 
Before 
Treatment 
After Treatment Total Number of 
Cases 
Grade G0 G1 G3 
1 G2 15 1 0 16 
2 G3 17 2 1 20 
3 G4 3 1 0 4 
4 Total 35 4 1 40 
 
 According to this study, 40 children came with the complaints of G2, G3, G4. 
After the treatment, out of 40 children 35 (87.5%) has completely cured. 
 
Table:39. Temperature 
S.No 
Before 
Treatment 
After Treatment Total Number of 
Cases 
Grade G0 G1 
1 G0 17 0 17 
2 G1 23 0 23 
3 Total 40 0 40 
 
According to this study, Out of 23 children who have reported with Low grade 
fever, 23 children (100%) have become normal after the treatment.  
Stastical Analysis    
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. STATA software was used to perform statistical analysis. 
Basic descriptive statistics include frequency distributions and cross- tabulations were 
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performed. Bar diagram were used to describe the value of different variables for 
pictorial representation. The quantity variables were expressed as Mean and standard 
deviation and qualitative data as percentage. A probability value of less than 0.05 was 
considered to indicate as statistical significance. Paired„t‟ test was performed for 
determining the significance between before and after treatment. 
Table:40. Statistical significance of treatment on clinical symptoms. 
Treatment Mean ± std E Value P Value 
Before 13.8 ± 2.22 
19.75 <0.0001 
After 2.35 ± 2.5 
 
The mean and standard deviation of Vali Kanam Before and after treatment were 
13.5 ± 2.22 and 2.35 ± 2.5 respectively. Which is statistically significant P <0.0001 t-
value =19.75.There is a highly significant difference between before and after treatment. 
i.e 83% reduction in the clinical symptoms after the treatment.  
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6. DISCUSSION 
“VALI KANAM” is the most common Respiratory tract infections of children 
encountered in primary health care in worldwide. Vali Kanam more or less resembles 
Acute Pharyngitis in modern literature. The disease is characterized by Cough, Sore 
throat, Poor appetite, Low grade fever.  
In the present study, forty cases were treated in the outpatient department, 
according to clinical features mentioned in textbook of Balavagadam. The choosen drug 
Vilva Ennai is indicated for Kanam and here a clinical trial is initiated with treating 
children. The diagnosis is confirmed based on clinical feautures and treated with the drug 
“VILVA ENNAI” and the prognosis is clearly observed. Modified Leicester cough 
questionnaire (LCQ), Sore throat and Appetite scoring system and temperature be 
measured in the under axilla are taken as the prognostic tool to evaluate the efficacy of 
the trial drug.   
The study is conducted after the proposal was screened by the Screening 
committee of National Institute of Siddha. The Clinical study has been approved by IEC 
of NIS, approval No: NIS/IEC/9/2014-15/17. The trial is registered in Clinical trial 
Registry of India with Reg.No.CTRI/2017/02/007753. The Authentication of ingredients 
of the trial drug was obtained from Medicinal Botanist Dr.D.Aravind,MD(S),MSc., 
National Institute of Siddha, Chennai. 
The trial drugs were prepared by the author in the Gunapadam practical laboratory 
of National Institute of Siddha, under the guidance and supervision of the guide. The trial 
drug was prepared by the standard operating procedure as mentioned in the protocol. 
Physicochemical analysis was done as a preliminary evaluation and the trial drug 
Vilva Ennai. Loss on drying (LOD) is a method of measuring the amount of water and 
volatile matters in a sample when the sample is dried. Low moisture content is always 
desirable for higher stability of drugs. In Vilva Ennai, the loss on drying at 105
o
C was 
found to be 0.9±0.43. So the determination of moisture content shows the good stability 
of the drug Vilva Ennai.     
The total Ash values are helpful in determining the quality and purity of drugs, 
especially in powder form. The total Ash value in Vilva Ennai found to be 0.588±0.11. 
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The minimal level of total ash shows the less inorganic residue and purity of the drug 
Vilva Ennai.    
Strongly Acidic nature of the drug can cause the harmful effects to the body, so 
the screening for the pH is important for drugs. It represents the chemical nature of the 
drug and the site of absorption of non-polar drug. The pH of Vilva Ennai is found to be 6, 
that is weekly acidic and safe in pH. The weekly acidic drugs are rapidly absorbed from 
stomach. So the drug Vilva Ennai can act rapidly on oral administration. 
           The refractive index is a measure of purity of a sample. It is a ratio of velocity of 
light in vacuum. If any adulteration is present in the sample the refractive index will 
increase or decrease, which is very helpful in determination of unsaturation. Refractive 
index increases with increase in unsaturation. Since the refractive index is 1.46 it 
interprets that there is no adulteration in the sample and degree of unsaturation is low. 
Iodine value, Saponification value is used to measure the relative degree of 
unsaturated fatty acid in the sample. Smaller the molar weight of the fat higher the 
saponification value. The saponification value indicates the mean molecular weight of 
fatty acid of triglycerides comprising of fat. Lower the saponification value larger the 
molecular weight of fatty acids and triglyceride vice versa. Since the Iodine value (mg 
I2/g) is 102 & saponification value (mg of KOH to saponify 1gm of fat) is 211. The 
observation shows medium chain fatty acid or triglycerides as the main component. 
Medium chain triglycerides passively diffuse from the GI Tract to the portal system. It 
facilitate easily absorbed and metabolization of the trial drug. 
 The trail drug Vilva Ennai shows the presence of Phytoconstituents such as 
Alkaloids, Steroids, Sugar, Phenols, Saponin an proteins. Alkaloids have anti-bacterial 
activity. So, it reduces the infection. Steroids helps as immune modulators and control the 
inflammation, So it may be reduce the symptoms of fever, cough, sore throat. Saponins 
have the activity of Alterative, Expectorant, Anti-spasmodic, anti- catarrhal, anti-oxidant, 
and anti-inflammatory. So it may reduce the symptoms of fever, cough, sore throat. 
Phenols have the activity of anti-microbial, anti-inflammation and anti-oxidant. So, it 
may reduce the infection.. 
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 The test reveals there the absence of heavy metals and micro- organism, Below 
limit of quantification of pesticides and aflatoxin.The trial drug is also free from 
microbial contamination, Aflatoxin and Pesticide residues. So it is safe to be 
administrated in children. There is no adverse effect produced by the trail drug Vilva 
Ennai during the entire course of treatment. 
 
 
The anti-inflammatory activity of the trial drug VILVA ENNAI was done at 
Noble Research Solutions, Sathyabama University, Chennai. In-vitro Anti-inflammatory 
activity of VILVA ENNAI was performed by protein (Albumin) denaturation method. 
The result obtained from the present study clearly indicates that the test drug was 
effective in inhibiting heat induced albumin denaturation. Maximum percentage 
inhibition of about 72.12% was observed at 500 μg/ml when compare to that of the 
Diclofenac sodium, a standard anti-inflammatory agent with the maximum inhibition 
86.16 % at the concentration of 100μg/ml. 
The Bio-chemical analysis revealed the presence of Chloride, Ammonium, 
Fluoride and Oxalate. 
            In clinical studies the patients were recruited for the trial based on inclusion and 
exclusion criteria and after getting the consent from the patient. 40 patients were included 
in this study. The 40 patients were treated in OPD of Ayothidoss Pandithar Hospital of 
National Institute of Siddha. Separate proforma was maintained for every patient. 
Progress chart was also maintained to monitor the clinical signs and symptoms of the 
disease.  
The treatment was aimed at normalizing the deranged thodams and providing 
relief from symptoms. Before treatment the patients were advised to adapt lifestyle 
modifications such as oil bath weekly once and to follow good dietary regimen. 
The patients were treated with trial drugs VILVA ENNAI for 5 days. Patients 
were instructed to take the medicines regularly and advised to follow pathiyam and to 
avoid exposure to allergic substances if any. Patients were asked to visit the hospital on 
6
th
 day for assessment. After completion of the study; the patients were advised to visit 
the Out-Patient ward of Department of Kuzhanthai Maruthuvam for 1 month for follow-
up. The results observed during the study period were discussed by the author below.   
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This study elicies the efficasy of “VILVA ENNAI” in relieving the symptoms of 
Vali kanam. 
CLINICAL REVIEW 
   Age 
Out of 40 patients, 60% of cases were 8-10 years, 40% of cases were 11-
12 years. The highest incidence was seen in the age group of 8-10 years. School 
going age group is most affected. 
 Sex 
Out of 40 patients 47.5% were male children and 52.5% were female 
children. According to this study both sexes were more or less equally affected 
which shows Vali Kanam is not predominant on sex.  
 Socio-economic status 
 About 7.5% patients were under upper class, 27.5% patients were under 
upper middle class, 60% patients were under Lower middle class and 5% patients 
were lower class. The highest incidence occurred in lower middle income group 
due to overcrowding and poor sanitation. 
 Seasonal variation 
Among 40 patients, 52.5 % were from Munpani kaalam, 45 % from 
Pinpani kaalam, 2.5%  from Koothir kaalam. The hieghest incidence was noted in 
munpanikaalam. 
 Food habits 
According to diet, Vegetarian 5%, Non vegetarian 95% were noted. The 
highest incidence was seen in Non-Vegetarian. But Vali Kanam has no influence 
on diet. 
 Nilam 
Among 40 patients, 80% were from Neithal land, 15 % from Marutham 
land, 0 % from Mullai land, and 5% from Kurinji land. Since this study was 
carried out in Chennai, the highest incidence of people seeking  treatment were 
from the sourrounding of Chennai and hence highest incidence was noted in 
Neithal nilam. 
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 Vali (Vatham) 
Due to the derangement of different vatha the following symptoms occur.  
According to vatham, derangement of Pranan was 100% due to poor appetite, 
Abanan was 17.5% due to constipation, Uthanan was 75% due to sore throat and 
difficulty in swallowing, samaanam was affected 100% due to derangement of 
other vatham and Kirukaran was deranged in 100% due to cough. 
 Azhal (Pitham) 
According to Pitham, derangement of Analapitham was 100% due to poor 
appetite and Ranjagapitham was deranged in 15% due to pallor of tongue and 
conjuctiva. 
 Iyyam (Kabam) 
 According to Kabam, derangement of Kelathagam was 100 % due to poor 
appetite and Avalambagam was deranged in 100%. 
 Ezhu udarkattugal 
According to the study, Saram was affected in 100% of cases due to 
presence of fatigue, Senneer was affected in 15% due to pallor of tongue and 
conjunctiva. 
 Envagai thervugal 
           According to this study, Out of 40 cases,  
 In 35% of the cases Mozhi was affected due to hoarseness of voice.  
 Malam was affected in 20% of patients due to constipation.  
 In 17.5% of cases Sparisam was affected due to fever. 
 In 10% 0f cases naa was affected due to pallor of the tongue.  
 In 10% of the cases vizhi was affected by due to pallor of the 
conjunctiva. 
   Naadi 
                    According to this study, Out of 40 cases, 
                  Vathapitham was observed in 50 % of cases,  
                 Pithavatham was observed in 40 % of cases,  
                 Pithakabam was observed in 10 % of cases. 
123 
 
       According to naadi, high distribution was observed in vali Azhal, Azhal vali 
and Azhal iyyam naadi. In siddha literature, the character of vali Azhal is mainly poor 
appetite, indigestion and nausea. 
 Neerkuri 
 Regarding moothiram, neerkuri showed straw coloured urine in all cases. 
 Neikuri  
In the present study, 27.5% had vatha neikuri, 30% was observed as pitha 
neikuri and 42.5 % was kaba neikuri. 
Statistical analysis 
       The clinical feature of Vali kanam, before and after treatment were 13.8±.22 and 
2.35 ± 2.5 respectively. The reduction in the symptoms is 83% from the start of the 
treatment. 
DRUG REVIEW 
The trial medicine Vilva Ennai is chosen for treatment of Vali kanam. The 
ingredients of this drug have the property of controlling the symptoms Vali kanam. 
             The pharmacological studies already carried out on the individual drugs also 
favour its effect in disease of Respiratory tract illness as given below: Aegle marmelose 
have a potent anti-inflammatory activity, anti-pyretic activity and anti- oxidant activity, 
Allium cepa have anti-inflammatory activity, anti- microbial activity and anti- oxidant 
activity, Indigofera tinctoria have anti-microbial activity and anti-oxidant, Terminalia 
chebula has anti-oxidant property and anti-microbial activity and Ricinus communis  
have anti-inflammatory activity and anti-oxidant activity. The results of the study suggest 
that treatment with VILVA ENNAI has significant improvement in patients with Vali 
kanam.  
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7. SUMMARY 
                    Acute inflammation of the throat is a frequent reason for medical 
consultations in all age groups. Although generally mild in nature, it may give rise to 
significant suffering and morbidity, including throat pain, pain on swallowing, high fever, 
difficulty in eating and drinking, and the need for time off work or school. The literature 
evidence of both the siddha and modern literatures were reviewed and the reviews and 
recent studies on the individual drugs of the trial drug were collected. Patients attending 
the OPD of NIS having the compliants of Vali kanam diagnosed clinically and the patients 
were observed for clinical diagnosis. Classical symptoms of Vali kanam emphasis with 
the symptoms of pharyngitis like cough, Sore throat, Poor appetite, Lowgrade fever. 
The Clinical study has been approved by IEC of NIS and  the trial was registered in 
Clinical trial Registry of India. The Authentication of ingredients of the trial drug was 
done obtained from Medicinal Botanist Dr.D.Aravind MD(S), M.Sc., National Institute 
of Siddha, Chennai. Purification of drugs and preparation of trial drug was done at 
Gunapadam Laboratory, Department of Gunapadam, NIS, Chennai. Biochemical 
Qualitative analysis of trial drug was done in Biochemistry laboratory, Department of 
Biochemistry, National Institute of Siddha, Chennai. Clinical   diagnosis of   Vali kanam 
was done on the   basis of   the clinical features   described in Balavagadam text.  
The patients with Vali kanam were recruited based on Inclusion and Exclusion 
criteria and a detailed study was done. Separate proforma was maintained for each patient 
along with progress chart to monitor the prognosis. The medicine chosen for clinical 
study of Vali kanam is Vilva Ennai administered internally one time in a day for 5 days.               
 All the patients were adviced to follow healthy dietary regimen during the 
treatment. The observation on effect of the therapy was encouraging. 
 The trial drug Vilva Ennai have potent anti-inflammatory activity. 
                The physicochemical analysis reveals the high saponification value and Iodine 
Value, Good refractive index. 
    The trial drug Vilva Ennai, shows the presence of Phytoconstituents such as 
Alkaloids, Phenols, Steroids, Sugar, Saponin and Protein and the absence of heavy metals 
and micro- organism, pesticides and aflatoxin.  
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    The biochemical analysis revealed the presence of Chloride, Ammonium, 
Fluoride & Oxalate.  
The patients have not complained of any adverse effects or difficulties during the 
course of treatment. Thus the drug is found to be safe and effective in the management of 
Vali kanam. The  clinical efficacy  of  the  drug  was  analyzed  statistically  on  all  the  
symptoms mentioned  in  the  assessment  criteria. The observation made during the 
clinical study showed that the trail drug vilva ennai was clinically effective.                                                                                                                                                                                                                                                    
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8. CONCLUSION 
              The Siddha system of medicines has certainty with safer medications to treat 
children. In the present study, the trial drug vilva ennai is treated in the children of age 
group, 8-12 years who are all diagnosed to have Vali kanam. The ingredients of  vilva 
ennai are feasible and useful and  these compounds may serve as potentially useful drug 
at a lower cost since most of them had anti-inflammatory, anti-pyretic activity. Clinical 
results were found as highly significant before and after treatment. i.e 83% reduction in 
clinical symptoms after the treatment. The present clinical study has established that 
vilva ennai is having good result in reducing the majority of the symptoms of vali 
kanam. This has inturn, provided a further research and opportunity for new drug 
established in the management of Vali kanam.  
By encouraging results of above study the drug may be taken for larger study in 
treatment of Vali kanam. 
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10. ANNEXURES 
                                            NATIONAL INSTITUTE OF SIDDHA 
             AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF VILVA ENNAI (A SIDDHA DRUG) IN THE TREATMENT  
OF VALI KANAM (ACUTE PHARYNGITIS) IN CHILDREN.                                           
1. S.No:    2. OP/ IP No:                           3. Name:          
4. Age:    5. Gender:    6. Date:       
7. Informant:    8. Reliability:    
 
SCREENING  FORM 
INCLUSION CRETERIA:          Yes        No 
Age: Between 8-12 years 
Cough   
Low grade fever                 
Sore throat      
 Loss of appetite      
EXCLUSION CRITERIA: 
Congenital heart disease  
Tonsillitis  
Bronchial asthma 
  Primary complex  
 Long term fever                             
ADMITTED TO THE STUDY   
     If Yes,    OPD                             IPD  
 
Signature of Guide     Signature of Principal Investigator 
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                                             NATIONAL INSTITUTE OF SIDDHA 
  AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 47. 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
 
CLINICAL EVALUATION OF VILVA ENNAI (A SIDDHA DRUG) IN THE 
TREATMENT OF VALI KANAM (ACUTE PHARYNGITIS) IN CHILDREN. 
 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
I, ____________________________________Studying as PG Scholar in the 
department of Kuzhandhai Maruthuvam at National Institute of Siddha, Tambaram 
Sanatorium is doing a clinical study on VALI KANAM (ACUTE PHARYNGITIS). In 
this regard, I am in a need to ask you few questions. I will maintain confidentiality of 
your response and data obtained from you. There will be no risk is involved by taking 
part in this study.  
           You can choose not to take part. You can choose not to answer a specific question. 
However, taking part in the study may be of benefit to the scientific community, as it may 
help us to understand the problem and potential solutions.              
             If you agree your child to be a participant in this study, he/she will be included in 
the study primarily by signing the consent form and then you will be given the internal 
medicine “VILVA ENNAI”(3 ml- Once a day in morning after food for 5days). 
             The information I am collecting in this study will remain between you and the 
principal investigator (myself). If you wish to find out more about this study before 
taking part, you can ask me any related questions or contact me through my mobile 
number: +91 74488 30555  
You can also contact the Member-secretary of Ethics committee, National 
Institute Siddha, Chennai 600047, Tel no: 91-44-22380789, for rights and participation in 
the study.  
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Njrpa rpj;j kUj;Jt epWtdk; 
mNahj;jpjhr gz;bjH kUj;Jtkid> nrd;id-47 
Foe;ij kUj;Jtj; Jiw 
tspfzk; Neha;f;fhd tpy;t vz;nza ;apd; ghpfhpg;Gj; jpwidf; fz;lwpAk; 
kUj;Jt gl;lNkw;gbg;G 
jfty; gbtk;  
Muha;r;rpahsH ngah; : kU.fp.mgpeah 
kUj;Jt Ma;tpw;fhd jfty; gbtk; 
 Njrpa rpj;j kUj;Jt epWtdj;jpy; Foe;ij kUj;Jtj; Jiwapy; gl;;l Nkw;gbg;G 
gapd;W tUk; kU.fp.mgpeah Mfpa ehd;; tspfzk; Neha;f;fhd tpy;t vz;nza;apd ; 
ghpfhpg;Gj; jpwidf;; fz;lwpAk; kUj;Jt Muha;r;rpapy; <Lgl;Ls;Nsd;. ,J rk;ge;jkhd 
Foe;ijapd; midj;J tptuq;fSk; ,ufrpakhf itf;fg;gLk; vd cWjp mspf;fpNwd;.  
,J Nghd;w 
tptuq;fis njuptpg;gjhy; jq;fSf;Nfh jq;fsJ Foe;ijf;Nfh jq;fspd; Ntiy 
jsj;jpNyh ve;j xU ghjpg;Gk; Vw;glhJ. ,jpy; gazg;gb Kjypa ve;j cjtpj;njhifAk; 
toq;fg;glkhl;lhJ.,e;j Muha;r;rpf;F Nehapduhf Nru;e;j gpwF cq;fSf;F tpUg;gk; 
,y;iynadpy; vg;NghJ Ntz;LkhdhYk; jq;fsJ Foe;ijia tpyf;fpf; nfhs;syhk;. 
,Ue;jhYk; ,e;j kUj;Jt Ma;tpy; Nrh;tjd; %ykhf jq;fsJ Foe;ijapd; Neha; 
FiwtJ kl;Lky;yhky; kUj;Jtj; Jiw rhHe;j ty;YeHfSf;F ,e;j Neha;f;fhd 
jPh;Tfis fz;lwptjw;F kpfTk; cjtpahf ,Uf;Fk;.,e;j Muha;r;rpf;F jq;fsJ 
tpUg;gj;jpd; Ngupy; jq;fsJ Foe;ijia cl;gLj;Jk; gl;rj;jpy; Kjd;ikahf xg;Gjy; 
gbtj;jpy; ifnaOj;jpl;l gpd;G jhq;fs; cs;kUe;jhf tpy;t vz;nza ; (3kp.fp) xU 
Ntis juNtz;Lk;. 
,e;j kUj;Jt Ma;tpd; njhlHghf cq;fsplkpUe;J Nrfupf;fg;gLk; midj;J tptuq;fSk; 
cq;fSf;Fk; Muha;r;rpahsuhd vdf;Fk; kl;LNk mwpe;jpUf;ff; $bajhf ,Uf;Fk;.,e;j 
Muha;r;rp rk;ke;jkhf kw;w tpguq;fisAk; Nehapd; jd;ik gw;wpAk; mwptjw;F 
Muha;r;rpahsuhd kU.,uh.ru];tjp ifNgrp vz; 766773440 njhlu;G nfhs;syhk;.NkYk; 
,e;j Muha;r;rp njhlu;ghf epWtd ePjpnewp FO,Njrpa rpj;j kUj;Jt epWtdk;, 
njhiyNgrpvz; 91-44-22380789 njhlu;G nfhs;syhk;. 
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NATIONAL INSTITUTE OF SIDDHA 
                         AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600047. 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF VILVA ENNAI (A SIDDHA DRUG) IN THE 
TREATMENT OF VALI KANAM (ACUTE PHARYNGITIS) IN CHILDREN. 
CONSENT FORM 
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent/guardian 
Date:       Signature : _________________ 
Station:       Name    : _________________ 
           CONSENT BY PARENT 
 I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my son/daughter body functions. 
 I am aware of my right to OPD my son/daughter out of the trail at any time during the 
course of the trail without having to give the reasons for doing so.  
 I, exercising my free power of choice, hereby give my consent to include my 
son/daughter as a subject in the clinical trial of „VILVA ENNAI‟ for the treatment of „VALI 
KANAM‟  
Date:       Signature  __________________ 
      Name   __________________ 
      Signature of witness  __________________ 
      Name   __________________
Relationship              _______________ 
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Njrpa rpj;j kUj;Jt epWtdk; 
mNahj;jpjhr gz;bjH kUj;Jtkid> nrd;id-47 
Foe;ij kUj;Jtj; Jiw 
tspfzk; Neha;f;fhd tpy;t vz;nza ;apd; ghpfhpg;Gj; jpwidf; fz;lwpAk; 
kUj;Jt Ma;T 
xg;Gjy; gbtk;  
Ma;thsuhy; rhd;wspf;fg;gl;lJ 
ehd; ,e;j kUj;Jt Ma;T Fwpj;j midj;J tpguq;fisAk; Nehahspapd; ngw;NwhUf;Fg; 
GhpAk; tifapy; vLj;Jiuj;Njd; vd cWjp mspf;fpNwd;. 
Njjp:        ifnahg;gk;: 
,lk;:         ngah;:  
Nehahspapd; ngw;Nwhh; xg;Gjy;  
vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk;>kUe;jpd; jd;ik kw;Wk; kUj;Jt 
topKiw gw;wpAk;> ,e;j kUj;Jtj;ijj; njhlh;e;J vdJ Foe;ijapd; cly; 
,af;fj;ijf; fz;fhzpf;fTk;>mjidg; ghJfhf;f gad;gLk; kUj;Jt Ma;Tfs; gw;wpAk; 
jpUg;jp mspf;Fk; tifapy; Ma;T kUj;Jtuhy; tpsf;fpf; $wg;gl;lJ. 
ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky; vg;nghOJ Ntz;LkhdYk; 
vd; Foe;ijia tpLtpj;Jf; nfhs;Sk; chpikiaj; njhpe;jpUf;fpNwd;.   
ehd; vd;Dila Rje;jpukhfj; Njh;T nra;Ak; chpikiaf; nfhz;L tspfzk; 
Neha;f;fhd tpy;t vz;nza ;apd; ghpfhpg;Gj;jpwid fz;lwpAk; kUj;Jt Ma;Tf;F vdJ 
Foe;ijia cl;gLj;j xg;Gjy; mspf;fpNwd;. 
Njjp:        ngw;nwhh; ifnahg;gk;: 
,lk;:       ngaH: 
       rhl;rpf;fhuu; ifnahg;gk;: 
       ngau;:  
       rhl;rpf;fhuu; cwTKiw: 
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                                         NATIONAL INSTITUTE OF SIDDHA 
                        AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 47. 
                          DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF VILVA ENNAI (A SIDDHA DRUG) IN THE 
TREATMENT OF VALI KANAM (ACUTE PHARYNGITIS) IN CHILDREN. 
                                                      
                                                      ASSENT FORM (by patient) 
I---------------------------------------------------- understand that my parents (mom and 
dad)/guardian have /has given permission (said it‟s okay) for me to take part in a project 
about CLINICAL EVALUATION OF VILVA ENNAI FOR VALI KANAM done by 
Dr.K.Abinaya. 
I am taking part because I want to take part. I have been told that I can stop at any time I 
want to do so and nothing will happen to me if I want to stop. 
 
 
 
     Date:                                                                                       Signature of the Patient 
     Station: 
                                                                                                    Signature of the Parent 
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Njrpa rpj;j kUj;Jt epWtdk; 
mNahj;jpjhr gz;bjH kUj;Jtkid> nrd;id-47 
Foe;ij kUj;Jtj; Jiw 
tspfzk; Neha;f;fhd tpy;t vz;nza ;apd; ghpfhpg;Gj; jpwidf; fz;lwpAk; 
kUj;Jt gl;lNkw;gbg;G 
xg;Gjy; gbtk; Foe;ijf;fhdJ 
 ______________________ Mfpa ehd; Njrpa rpj;j kUj;Jt epWtdj;jpy; 
gl;lNkw;gbg;G Foe;ij kUj;Jtj; Jiwapy; gapYk; kU.fp.mgpeah mtu;fshy; 
elj;jg;gLk;; tspfzk; Neha;f;fhd tpy;t vz;nza ;apd; ghpfhpg;Gj; jpwidf;; 
fz;lwpAk; kUj;Jt Ma;tpy; gq;Nfw;gjw;F vdJ ngw;NwhH/fhg;ghsu; 
jpU/jpUkjp.________________________rk;kjk; njuptpj;jpUg;gij ed;F mwpNtd;.  
 vdf;F ,e;j Muha;r;rp gw;wp; GhpAk; tifapy; vLj;Jiuf;fg;gl;Ls;sJ. 
,t;thuha;r;rpapy; ,Ue;J vg;NghJ Ntz;LkhdhYk; tpyf vdf;F chpik ,Uf;fpd;wJ 
vd;gijG; gw;wpAk; ed;F njupe;Jnfhz;L ,e;j Muha;r;rpapy; gq;Nfw;f rk;kjpf;fpNwd;.  
Njjp:       Foe;ijapd; ifnahg;gk;: 
,lk;:        ngah;: 
       ngw;nwhh; ifnahg;gk;: 
       ngaH: 
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   NATIONAL INSTITUTE OF SIDDHA 
                      AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 47.      
                       DEPARTMENT OF KUZHANDHAI MARUTHUVAM                                                                                                                                                             
 CLINICAL  EVALUATION  OF  VILVA ENNAI  (A SIDDHA DRUG)  IN  THE 
TREATMENT  OF  VALI KANAM  (ACUTE PHARYNGITIS)  IN  CHILDREN. 
CASE REPORT FORM 
Demographic data: 
 Patient Id : OP/IP No: Visit Date :  
Name   
Age      
Date of Birth   
 
Gender                 
Male                                                                    
Female 
Father/ Mother /Guardian Name   
Father Occupation   
Father Monthly  Income   
Religion   
Socioeconomic Status   
Informant   
Postal Address  
Contact Number  
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Complaints and Duration: 
 
 
 
 
Present illness:  
 
 
 
 
History of Past Illness: 
History / Symptoms / Signs Yes No If, Yes Details 
Any Similar Complaints    
Bronchial Asthma    
Dust Allergy    
Hospitalization    
Any other    
 
Family History: 
Any Hereditary/ Familial Disease                  Yes                      No    
If Yes, Details ___________________ 
 
Immunization History:  
Proper Immunization given     Yes                   No             
................................................. 
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Food habits: 
1. Veg  2. Non-Veg   
 
General assessment: 
         
1. Pica     Yes      No 
2. Nail biting   Yes  No 
3. Bowel habits   Normal  Abnormal  
General Examination: 
1. Pallor    Yes  No 
2. Jaundice   Yes  No 
3. Cyanosis   Yes  No 
4. Clubbing   Yes  No 
5. Pedal oedema   Yes  No 
6. Lymph adenopathy  Yes  No 
Vital signs: 
1. Pulse rate   _____ / min 
2. Heart rate   _____ / min 
3. Respiratory Rate  _____ / min 
4. Temperature  _____o F 
Anthropometry: 
          Height :  ________ cm 
          Weight :  ________ kg 
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Systemic Examination:                  
Examination of Respiratory System 
A)  Inspection: 
Shape    :  Normal             Barrel Shaped          Pigeon chest  
Shoulder Drooping     :   Absent             Present 
Intercostal spaces  :   Normal            Bulge                        Indra-wing     
Spine                           :   Normal            Kyphosis                   Scoliosis 
Supraclavicular fossae:   Normal            Flattening                  Hollowing 
Position of mediastinum: 
        Trail‟s sign:   Present           Absent 
Apical impulse _____________________ 
B)  Palpation: 
Tenderness                             Yes                     No 
                                            If Yes ____________________ 
Tactile vocal Fremitus:        Normal and Equal   
         Increased 
         Decreased 
C)  Percussion:         
Percussion on all areas:       Normal                     
         Hyper resonance                                                            
         Dullness 
D)  Auscultation:  
Intensity of breath sounds:  
                   Normal      Decreased   Increased   
Vocal resonance: 
                   Normal      Decreased   Increased   
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Adventitious sounds: 
                   Wheeze  Crepitation  Rub                      None  
Other systems:   
        Normal           Affected         
Cardio vascular system: 
Gastro intestinal system: 
Musculoskeletal system:  
Central nervous system: 
Endocrine system: 
Nilam: 
            Kurinji                  Mullai      Marutham             Neithal             Paalai 
Kaala Iyalbu:  
 Kaarkalam    Koothirkaalam         Munpanikaalam  
 Pinpanikaalam              Illavenirkaalam          Muthuvenirkaalam 
Yaakai: 
 Vatham              Vatha Pitham           Vatha Kabam 
 Pitham    Pitha vatham           Pitha Kabam 
 Kabam               Kaba Vatham           Kaba Pitham 
Gunam:  
 Sathuvam   Rasatham           Thamasam 
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Pori / Pulangal:   
 Normal     Affected      Normal     Affected          Remarks 
Mei / Unarvu 
Vaai / Suvai  
Kan / Parvaai  
Mooku / Naatram 
Sevi / Oli 
Kanmendhirium / Kanmavidayam: 
       Normal     Affected       Normal          Affected          Remarks 
Kai / dhanam 
Kaal / ghamanam 
Vaai / vaku 
Eruvai / visarkam 
Karuvai / anantham 
Uyir Thathukkal 
Vatham: 
   Normal Affected  Remarks 
Pranan  
Abanan 
Viyanan  
Uthanan 
Samanan 
Nagan  
Koorman 
Kirukaran  
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Devathathan   
Dhanajeyan      
Pitham  
   Normal Affected  Remarks 
 
Analam  
Ranjagam    
Saathagam   
Alosagam  
Prasagam 
Kabam:  
   Normal Affected  Remarks 
Avalambagam    
Kilethagam   
Pothagam  
Tharpagam   
Santhigam  
Udalthathukkal: 
   Normal Affected  Remarks 
Saaram 
Senneer  
Oon  
Kozhuppu 
Enbu 
Moolai 
Sukilam / Suronitham   
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Envagai Thervugal:  
                                   Normal  Affected  Remarks 
a) Naa  
 Niram 
 Thanmai 
 Suvai 
b) Niram   
c) Mozhi   
d) Vizhi  
 Niram 
 Thanmai 
 Parvai 
e) Sparisam  
f) Malam 
 Niram    
 Nurai    
 Elagal    
 Erugal    
g) Moothiram 
    Neerkuri        
Niram     
 Edai     
 Nurai              
 Manam             
 Enjal                
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    Neikuri 
 Vatham           Pitham                 Kabam             Others 
h) Naadi 
            Vadham       Pitham     kabam 
            Vatha Pitham                Pitha Vatham  Kaba Vatham 
 Vatha Kabam                  Pitha Vabam                      Kaba vatham 
 
Clinical Assessment: 
S.No Clinical Symptoms 1
st
 day 6
th 
day 
1. Cough   
2. Low grade fever   
3. Sore throat   
4. Loss of appetite   
5. Excessive Thirst   
6. Borborygmus   
7. Dysuria   
 
Cough Assessment: 
(Each item carries two points and the total score will be assessed from the following) 
                                                                             Before Treatment    After Treatment               
1. Had chest pain or stomach pain during cough             
2. Sputum production while coughing                     
3. Sleep disturbances due to cough  
4. Cough interrupting conversation  
5. Cough present at rest  
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SORE THROAT SCALE:                                                      
G0 -Normal                         
G1 -Mild discomfort 
G2 -Hoarsness of voice only. 
G3 -Hoarsness of voice associated with Throat pain while speaking. 
G4 -Hoarsness of voice associated with throat pain and difficulty to swallowing. 
G5 -Severe throat pain with all above symptoms. 
 
APPETITE SCALES:                                                        
G0 -Normal                  
G2 -Mild appetite but eating time being 
G3 -Interest only to take junk foods 
G4 -No interest to take any type of food but on compulsion he/she takes foods. 
G5 -doesn‟t takes food even on compulsion. 
 
TEMPERATURE:                                                           
G0 –Normal (98.6 F)             
G1 –Low grade fever (99-100.4 F) 
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Laboratory Investigations : 
 
Diagnosis   ______________________________________ 
Drug Issued :  ___________________ 
Date   :  ___________________     
Station  :  ___________________  
 
Signature of the Guide                                                    Signature of Principal Investigator 
Signature of the HOD 
Routine Blood Investigations Normal values 
 
Before TMT 
Date: 
 
After TMT 
Date: 
T.RBC (milli /cu.mm)        4-4.9   
 
ESR (mm) 
½ hr. 0- 4   
1 hr.        0-13   
T.WBC (milli /cu.mm) 5000-14500   
Differential  
   Count (%) 
Polymorphs 40-75   
Lymphocytes 28-48   
Monocytes 3-6   
Eosinophils 0-3   
Basophils 0-1   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF VILVA ENNAI (A SIDDHA DRUG) IN THE 
TREATMENT OF VALI KANAM (ACUTE PHARYNGITIS) IN CHILDREN. 
 
  FORM IX-DIETARY ADVICE FORM 
 
 THINGS TO TAKE  THINGS TO AVOID 
Milk with palm sugar Refridged items 
 
Tulsi leaf juice Tin and can foods, broiler chicken. 
 
Fresh vegetable soups/Country chicken or 
mutton soups 
Cream containing biscuits and cakes 
 
Boiled water/Baked foods like idly Junk and fast foods 
 
Pepper, turmeric and cumin seeds White sugar 
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                                           NATIONAL INSTITUTE OF SIDDHA 
                      AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 47. 
                              DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF VILVA ENNAI (A SIDDHA DRUG) IN THE TREATMENT 
OF VALI KANAM (ACUTE PHARYNGITIS) IN CHILDREN.                                                                             
1.  S.No:    2. OP/ IP No:               3. Name:    
4. Age:     5. Gender:   6. Date of Enrollment:      
7. Informant:    8. Reliability:   
     DRUG COMPLIANCE 
Name of the drug                           : vilva ennai 
Form of the drug                            : oil 
Administration                                : per oral 
Dose & duration                               : 3 ml – od for 5 days  
Amount of drug given                      :    
Amount of drug returned                   : 
 
 
 
 
Date:      Signature of Principal Investigator 
Signature of the Guide              Signature of HOD 
DAY DATE OF  DRUG  INTAKE MORNING 
DAY 1   
DAY 2   
DAY 3   
DAY 4   
DAY 5   
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 NATIONAL INSTITUTE OF SIDDHA 
    AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 47. 
      DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF VILVA ENNAI (A SIDDHA DRUG) IN THE TREATMENT 
OF VALI KANAM (ACUTE PHARYNGITIS) IN CHILDREN. 
1. S.No:   2. OP/ IP No:   3. Name:                       
4. Age:   5. Gender:   6. Date of Enrollment:      
7. Informant:    8. Reliability:   
      
     ADVERSE REACTION 
 Date of Occurrence      : 
Date of Withdrawal from trial  : 
Description of Adverse reaction : 
Clinical Condition                   : 
 
 
 
 
Date:       Signature of Principal Investigator 
 
Signature of Guide      Signature of HOD 
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        NATIONAL INSTITUTE OF SIDDHA 
                         AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 47. 
             DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
CLINICAL EVALUATION OF VILVA ENNAI (A SIDDHA DRUG) IN THE TREATMENT        
OF VALI KANAM (ACUTE PHARYNGITIS) IN CHILDREN. 
1. S.No:       2. OP/ IP No:                           3. Name:                                                   
4. Age:          5. Gender:      6. Date of Enrollment:       
7.  Informant:         8. Reliability:   
WITHDRAWAL FORM 
Date of trial commencement   : 
Date of withdrawal from trial   : 
Reason(s) for withdrawal    
Long absence at reporting  : Yes / No 
Irregular treatment    : Yes / No 
Shift of locality    : Yes / No 
Complication adverse reactions if any: Yes / No 
Exacerbation of symptoms  : Yes / No 
Patient not willing to continue : Yes / No 
 
Date:       Signature of Principal Investigator 
      
 
Signature of the Guide     Signature of HOD   
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1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR  
SIDDHA DRUGS 
 
 
 
 
Please note:  i. All consumers / patients and reporters information will remain confidential. 
                             ii. It is requested to report all suspected reactions to the concerned, even if  
     it does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
 
 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / Female  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
 
Date and time  of initial 
observation 
 Season: 
Description of reaction   
 
 Geographical area: 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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3. List of all medicines / Formulations including drugs of other systems used by the patient 
during the reporting period: 
 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle – 
Adjuvant 
Date  Diagnosis for which 
medicine taken  
Starting Stopped 
Siddha 
 
 
 
 
     
Any other system 
of medicines 
 
 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic: 
 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained from    
e) Composition of the 
formulation / Part of the drug 
used 
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b) Dietary Restrictions if any 
c) Whether the drug is consumed under institutionally qualified medical supervision or used as 
self medication.  
d) Any other relevant information. 
 
5. Treatment provided for adverse reaction: 
 
6. The result of the adverse reaction / side effect / untoward effects (please complete the 
boxes below) 
 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If yes, 
give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
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9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
 
11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
 
Address: 
 
Telephone / E – mail if any : 
 
 
 
Signature of the reporter:       Date: 
 
 
Please send the completed form to:  
           The Director 
            National Institute of Siddha, 
                                                                  (Pharmacovigilance Regional Centre For Siddha Medicine), 
                                                                 Tambaram Sanatorium, Chennai-600 047. 
                                                                  (O) 044-22381314       Fax : 044 – 22381314 
        Website: www.nischennai.org  
Name & address of the RRC-
ASU / PPC-ASU 
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        Email: nischennaisiddha@yahoo.co.in   
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * *  
This filled-in ADR report may be sent within one month of observation /occurrence of ADR   
 
 
 
Date:                                                                              
Station:  
 
 
 
Date:      
Station: 
Signature of the Investigator:                                                 
Signature of the Lecturer:                                                                              Signature of the HOD  
  
 
 
Who Can Report?     
 Any Health care professionals like Siddha Doctors / Nurses / Siddha 
Pharmacists / Patients etc.  
What to Report? 
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence and protected to the fullest 
extent.  
 Submission of report will be taken up for remedial measures only not for legal 
claim  










